<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        50-370-13
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2013
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        SEVIKAR 20/10MG FILM COATED TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        OLMESARTAN MEDOXOMIL,AMLODIPINE BESILATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        20,10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        86.90
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C09DB02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Sevikar contains two substances called olmesartan medoxomil and amlodipine<br />)as amlodipine besilate(. Both of these substances help to control high blood<br />pressure.<br />&bull; Olmesartan medoxomil belongs to a group of medicines called &quot;angiotensin-II<br />receptor antagonists&quot; which lower blood pressure by relaxing the blood vessels.<br />&bull; Amlodipine belongs to a group of substances called &quot;calcium channel blockers&quot;.<br />Amlodipine stops calcium from moving into the blood vessel wall which stops the<br />blood vessels from tightening thereby also reducing blood pressure.<br />The actions of both these substances contribute to stopping the tightening of<br />blood vessels, so that blood vessels relax and blood pressure decreases.<br />Sevikar is used for the treatment of high blood pressure in patients whose<br />blood pressure is not controlled enough with either olmesartan medoxomil or<br />amlodipine alone.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- If you are allergic )hypersensitive( to olmesartan medoxomil or to amlodipine<br />or a special group of calcium channel blockers, the dihydropyridines, or to the<br />other ingredients named under section 7 )further information(.<br />- If you are more than 3 months pregnant )It is also better to avoid SEVIKAR in<br />early pregnancy&ndash; see section )Pregnancy and breast-feeding(.<br />- If you are breast-feeding or about to start breast-feeding. SEVIKAR is not re<br />commended for mothers who are breast-feeding, and your doctor may choose<br />another treatment for you if you wish to breast-feed.<br />- Sevikar should not be co-administered with aliskiren in patients with diabetes<br />mellitus or renal impairment<br />- If you suffer from low heart output because of a serious heart problem or heart<br />attack or if you have experienced a heart attack )acute myocardial infarction(<br />within the last 4 weeks.<br />- If you experience pain or discomfort in the chest at rest or during night<br />)unstable angina pectoris(.<br />- If you have severe hepatic insufficiency and biliary obstruction.<br />- Children and adolescents )under 18( SEVIKAR is not recommended for children<br />and adolescents under the age of 18.</p><p>Tell/consult your doctor before using SEVIKAR:<br />- If you are allergic )hypersensitive( to olmesartan medoxomil or to amlodipine<br />or a special group of calcium channel blockers, the dihydropyridines, or to the<br />other ingredients named under section 7)further information(.<br />- If you think you may be allergic, talk to your doctor before taking SEVIKAR.<br />- If you are more than 3 months pregnant. )It is also better to avoid SEVIKAR in<br />early pregnancy &ndash; see section )Pregnancy and breast-feeding(.<br />- Dual Blockade of the Renin-Angiotensin-aldosterone System )RAAS(:<br />- Combination of Sevikar with ACE inhibitors, or aliskiren may cause increased<br />risks of hyperkalemia, worsening of kidney function and hypotension.<br />Therefore, this combination should not be used, especially in patients with<br />kidney problems.<br />- If you have severe liver problems, if bile secretion is impaired or drainage of bile<br />from the gallbladder is blocked )e.g. by gallstones(, or if you are experiencing<br />any jaundice )yellowing of the skin and eyes(.<br />- if you suffer from low heart output because of a serious heart problem or heart<br />attack or if you have experienced a heart attack )acute myocardial infarction(<br />within the last 4 weeks.<br />- If you experience pain or discomfort in the chest at rest or during night<br />)unstable angina pectoris(.<br />- If you suffer from Severe hepatic insufficiency and biliary obstruction<br />Pregnancy and breast-feeding:<br /><strong>Pregnancy:</strong><br />You must tell your doctor if you think that you are )or might become( pregnant.<br />Your doctor will advise you to stop taking SEVIKAR before you become pregnant<br />or as soon as you know you are pregnant and will advise you to take another<br />medicine as SEVIKAR is not recommended in early pregnancy, and must not<br />be taken when more than 3 months pregnant, as it may cause serious harm to<br />your baby if used after the third month of pregnancy. If you become pregnant<br />during therapy with SEVIKAR, please inform and see your physician without<br />delay.<br />Breast-feeding<br />Tell your doctor if you are breast-feeding or about to start breast-feeding.<br />SEVIKAR is not re commended for mothers who are breast-feeding, and your<br />doctor may choose another treatment for you. Ask your doctor or pharmacist<br />for advice before taking any medicine if you are pregnant or breast-feeding.<br />Special conditions:<br /><strong>Hypotension in Volume- or Salt-Depleted Patients</strong><br />Symptomatic hypotension may occur after initiation of treatment with<br />olmesartan medoxomil. Patients with an activated reninangiotensin system,<br />such as volume- and/or salt-depleted patients )e.g., those being treated with<br />high doses of diuretics( may be particularly vulnerable.<br />Treatment with SEVIKAR should start under close medical supervision. If<br />hypotension does occur, the patient should be placed in the supine position<br />and, if necessary, given an intravenous infusion of normal saline. A transient<br />hypotensive response is not a contraindication to further treatment, which<br />usually can be continued without difficulty once the blood pressure has<br />stabilized.<br />Severe aortic stenosis<br />Caution, as with any other peripheral vasodilator, should be exercised when<br />administering SEVIKAR, particularly in patients with severe aortic stenosis<br />although acute hypotension has rarely been reported after oral administration<br />Patients with Severe Obstructive Coronary Artery Disease<br />Patients, particularly those with severe obstructive coronary artery disease,<br />may develop increased frequency, duration, or severity of angina or acute<br />myocardial infarction on starting calcium channel blocker therapy or at the time<br />of dosage increase. The mechanism of this effect has not been elucidated.<br />Patients with Congestive Heart Failure<br />Calcium channel blockers in general should be used with caution in patients with<br />heart failure. Although in clinical trials on Amlodipine There was no evidence<br />of worsening of heart failure based on measures of exercise tolerance &amp; there<br />was no overall adverse effect on survival or cardiac morbidity )as defined by<br />life-threatening arrhythmia, acute myocardial infarction, or hospitalization for<br />worsened heart failure(.<br />Patients with Impaired Renal Function<br />Changes in renal function may be anticipated in susceptible individuals<br />treated with olmesartan medoxomil as a consequence of inhibiting the reninangiotensin-aldosterone system. In patients whose renal function may depend<br />upon the activity of the renin-angiotensin-aldosterone system )e.g., patients<br />with severe congestive heart failure(, treatment with angiotensin converting<br />enzyme inhibitors and angiotensin receptor antagonists has been associated<br />with oliguria or progressive azotemia and )rarely( with acute renal failure and/<br />or death. Similar effects may occur in patients treated with SEVIKAR due to the<br />olmesartan medoxomil component<br />Patients with Hepatic Impairment<br />Since amlodipine is extensively metabolized by the liver and the plasma<br />elimination half-life )t1/2( is 56 hours in patients with severely impaired<br />hepatic function, caution should be exercised when administering SEVIKARto<br />patients with severe hepatic impairment.<br />Elderly patients<br />In Patients over 65 years of age, doctor will regularly check blood pressure at<br />any dose increase, to make sure that blood pressure does not become too low<br />Black patients<br />As with other similar drugs the blood pressure lowering effect of SEVIKAR can<br />be somewhat less in black patients.<br />Driving and using machines<br />You may feel sleepy or dizzy while being treated for your high blood pressure.<br />If this happens, do not drive or use machines until the symptoms wear off. Ask<br />your doctor for advice.<br />Tell your doctor if you have any of the following health problems:<br />- Kidney problems or a kidney transplant.<br />- Liver disease.<br />- Heart failure or problems with your heart valves or heart muscle.<br />- Severe vomiting, diarrhea, treatment with high doses diuretics or if you are on<br />a low salt diet.<br />- Increased levels of potassium in your blood.<br />- Problems with your adrenal glands )hormone producing glands on top of the<br />kidneys(.<br />- As with any medicine which reduces blood pressure, an excessive drop in blood<br />pressure in patients with blood flow disturbances of the heart or brain could<br />lead to a heart attack or stroke. Your doctor will therefore check your blood<br />pressure carefully.<br />Taking other medicines<br />Tell your doctor or pharmacist if you are taking or have recently taken any of the<br />following medicines:<br />- Dual RAAS Blockade, The combination of Sevikar with Aliskiren, ACEIs or<br />other ARBs is contraindicated in patients with diabetes mellitus or renal<br />impairment. Dual blockade )e.g by adding ACE inhibitor to Sevikar( should not<br />be used, especially in patients with Kidney problems.<br />- Potassium supplements, salt substitutes containing potassium, diuretics<br />or heparin )for thinning the blood and prevention of blood clots(. Using these<br />medicines at the same time as SEVIKAR may raise the levels of potassium in<br />your blood.<br />- Lithium )a medicine used to treat mood swings and some types of depression(<br />used at the same time as SEVIKAR may increase the toxicity of lithium. If you<br />have to take lithium, your doctor will measure your lithium blood levels.<br />- Non-steroidal anti-Inflammatory Drugs )NSAIDs, medicines used to relieve<br />pain, swelling and other symptoms of inflammation, including arthritis( used at<br />the same time as SEVIKAR may increase the risk of kidney failure. The effect of<br />SEVIKAR can be decreased by NSAIDs.<br />- Other blood pressure lowering medicines, as the effect of SEVIKAR can be<br />increased.<br />- Certain antacids )indigestion or heartburn remedies(, as the effect of SEVIKAR<br />can be slightly decreased.<br />- Medicines used for HIV/AIDS )e.g. ritonavir( or for the treatment of fungal<br />infections )e.g. ketoconazole, itraconazole(.<br />- Diltiazem, an agent used for heart rhythm problems and high blood pressure.<br />- Anticonvulsant agents used for epilepsy )e.g. carbamazepine, phenobarbital,<br />phenytoin, fosphenytoin, primidone(.<br />- Rifampicin, an agent used for tuberculosis and other infections.<br />- St. John&rsquo;s wort )Hypericum perforatum(, a herbal remedy.<br />- Sildenafil, an agent used for the treatment of inability to get or maintain an<br />erection, as the blood pressure lowering effect can be increased.<br />Please tell your doctor or pharmacist if you are taking or have recently<br /><strong>taken any other medicines, including medicines obtained without a<br />prescription</strong>.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you.<br />Check with your doctor or pharmacist if you are not sure.<br />&bull; The recommended dose of Sevikar is one tablet per day.<br />&bull; The tablets can be taken with or without food. Swallow the tablet with some<br />fluid )such as a glass of water(. The tablet should not be chewed. Do not take<br />them with grapefruit juice.<br />&bull; If possible, take your daily dose at the same time each day, for example at<br />breakfast time.<br />Maximum antihypertensive effects are attained within 2 weeks after a change<br />in dose.<br />If you take more Sevikar than you should<br />If you take more tablets than you should you may experience low blood pressure<br />with symptoms such as dizziness, fast or slow heart beat.<br />If you take more tablets than you should or if a child accidentally swallows some,<br />go to your doctor or nearest emergency department immediately and take your<br />medicine pack or this leaflet with you.<br />Excess fluid may accumulate in your lungs )pulmonary oedema( causing<br />shortness of breath that may develop up to 24-48 hours after intake.<br />If you forget to take Sevikar<br />If you forget to take a dose, take your normal dose on the following day as usual.<br />Do not take a double dose to make up for a forgotten dose.<br />If you stop taking Sevikar<br />It is important to continue to take Sevikar unless your doctor tells you to stop.<br />If you have any further questions on the use of this medicine, ask your<br /><strong>doctor or pharmacist.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Although not many people may get them, the following 2 side effects can<br /><strong>be serious:</strong><br />&bull; Allergic reactions with swelling of the face, mouth and/or larynx together with<br />itching and rash may occur during treatment with SEVIKAR. If this happens<br />stop taking SEVIKAR and talk to your doctor immediately.<br />&bull; SEVIKAR can cause the blood pressure to fall too low in susceptible individuals.<br />This could cause severe light-headedness or fainting. If these happen you have<br />to stop taking SEVIKAR, talk to your doctor immediately and lie down flat.<br />Other possible side effects with SEVIKAR:<br />- Common )affecting less than 1 in 10 patients(: Dizziness; headache;<br />swelling of ankles, feet, legs, hands, or arms; tiredness.<br />- Uncommon )affecting less than 1 in 100 patients(: Dizziness on<br />standing up; lack of energy; tingling or numbness of hands or feet; vertigo;<br />strong heart beat; fast heart beat; low blood pressure with symptoms<br />such as dizziness, light-headedness; labored breathing; cough; nausea;<br />vomiting; indigestion; diarrhea; constipation; dry mouth, upper abdominal<br />pain; skin rash; muscle spasms; pain in arms and legs; back pain; feeling<br />more of an urge to pass urine; sexual inactivity; inability to get or<br />maintain an erection; weakness. Some changes in blood test results have also<br />been seen and include the following: increased as well as decreased blood<br />potassium levels, increased blood creatinine levels, increased uric acid levels,<br />increases in a test of liver function )gamma glutamyl transferase levels(.<br />- Rare )affecting less than 1 in 1,000 patients(: Drug hypersensitivity;<br />fainting; rash with hives; swelling of face.<br />- Not known)frequency cannot be estimated from the available data(: If<br />you experience yellowing of the whites of the eyes, dark urine, itching of the<br />skin, even if you started therapy with Sevikar long ago, contact your doctor<br />immediately who will evaluate your symptoms and decide on how to continue<br />your blood pressure medication,<br />Further side effects reported with use of olmesartan medoxomil or<br /><strong>amlodipine alone:</strong><br />- Olmesartan Medoxomil<br />Angina )pain or uncomfortable feeling in the chest, known as angina pectoris(;<br />bronchitis; sore throat; runny or stuffy nose; abdominal pain; stomach ache; pain<br />in the joints or bones; blood in the urine; infection of the urinary tract; chest pain;<br />flu-like symptoms; pain, changes in blood test results as increased fat levels<br />)hypertriglyceridaemia( and increase in tests of liver and muscle function also<br />additional side effects, all at very rare frequency: Reduced number of a type of<br />blood cells, known as platelets, which can result in easily bruising or prolonged<br />bleeding time; itching; eruption of the skin; swelling of the tongue or face; allergic<br />skin rash; muscular pain; acute kidney failure and kidney insufficiency; blood<br />urea increased; feeling unwell. In elderly patients the frequency of blood<br />pressure fall causing severe light-headedness or fainting is slightly increased<br />from rare to uncommon.<br />-Amlodipine<br />Redness and warm feeling of the face; abdominal pain; a reduction in the<br />number of white cells in the blood, which could increase the risk of infections;<br />a reduction in the number of platelets in the blood; breast enlargement in men;<br />increase in blood glucose; sleep disorder; irritability; depression; confusion;<br />mood changes including feeling anxious; feeling unwell; shiver; excessive<br />sweating; taste changes; tingling or numbness of hands or feet; visual<br />disturbances; tinnitus; chest pain; aggravation of angina )pain or uncomfortable<br />feeling in the chest(; inflammation of blood vessels; runny or stuffy nose;<br />thickening of gums; inflammation of stomach lining; elevated liver enzymes;<br />yellowing of the skin and eyes; inflammation of the liver or the pancreas;<br />eruption of the skin; itching; loss of hair; discoloration of the skin; purplish spots<br />or patches on the skin due to small hemorrhages )purpura(; isolated cases of<br />allergic reactions )itching, rash, swelling of the face, mouth and/or larynx, other<br />allergic conditions with inflammation and peeling of the skin, sometimes lifethreatening(; pain of muscles or joints; increase or decrease in weight. Isolated<br />cases of heart attack and irregular heart beat and angina have been reported in<br />patients with coronary artery disease, but a clear association with Amlodipine<br />has not been established.<br />If any of the side effects get serious, or if you notice any side effects not<br /><strong>listed in this leaflet, please tell your doctor or pharmacist.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.<br />Store below 30&deg;C.<br />Do not use SEVIKAR after the expiry date stated on the carton or label.<br /><br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>&bull; The active substances</strong> are Amlodipine Besilate at a dose equivalent to 5 or 10<br />mg and olmesartan medoxomil at a dose equivalent to 20 or 40 mg<br /><strong>&bull; The other ingredients</strong> are silicified microcrystalline cellulose, starch,<br />croscarmellose sodium, magnesium stearate and Opadry white )SEVIKAR&reg;<br />20/5mg(, opadry yellow )SEVIKAR&reg; 40/5mg(, opadry orange )SEVIKAR&reg;<br />20/10mg(, opadry red )SEVIKAR&reg; 40/10mg(.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                - SEVIKAR® 20/5 mg is round, white, film coated tablet, Coded by 311 on one
side and plain on the other side. Packs of 28 film coated tablets
- SEVIKAR® 20/10 mg is round, grayish orange, film coated tablet, Coded by
275 on one side and plain on the other side. Packs of 28 film coated tablets
- SEVIKAR® 40/5 mg is round, creamy, film coated tablet, Coded by 277 on one
side and plain on the other side. Packs of 28 film coated tablets
- SEVIKAR® 40/10 mg is round, brownish red, film coated tablet, Coded by 273
on one side and plain on the other side. Packs of 28 film coated tablets

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>SAJA Pharmaceuticals<br />Saudi Arabian Japanese pharmaceutical company limited<br />Jeddah &ndash; Kingdom of Saudi Arabia<br />Under license from<br /><strong>Daiichi Sankyo Co. Ltd.<br />Tokyo-Japan<br />For any information about SEVIKAR&reg;, please contact:</strong><br />SAJA Pharmaceuticals<br />Jeddah &ndash; Saudi Arabia<br />P.O. Box: 42600, Jeddah 21551, KSA<br />Tel: + 966 12 6066667<br />sajapharma.com<br />This leaflet was last revised in }August/2023{; version number }00{<br /><strong>-To report any side effect )s(</strong><br /><strong>&bull; Saudi Arabia</strong><br />- The National Pharmacovigilance Centre )NPC(:<br />- SFDA Call Center: 19999<br />- E-mail: npc.drug@sfda.gov.sa<br />- Website: https://ade.sfda.gov.sa<br /><strong>&bull; Other GCC States and other Countries:</strong><br />- Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                August/2023
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يحتــوي ســيفيكار علــى اثنيــن مــن الأدويــة الخافضــة لضغــط الــدم المرتفــع همــا أولميســارتان<br />ميدوكســوميل والأملوديبيــن (الأملوديبيــن بيســلات.) تســاعد هــذه المــواد فــي الســيطرة علــى<br />ارتفــاع ضغــط الــدم.<br />&bull; أولميســارتان ميدوكســوميل ينتمــي إلــى مجموعــة مــن الأدويــة تســمى &quot; حاصــرات مســتقبل<br />هرمــون الأنجيوتنســين &quot;٢الــذي يعمــل علــي منــع التأثيــرات القابضــة للأوعيــة الدمويــة الخاصــة<br />بهرمــون الأنجيوتنســين ٢ممــا يــؤدي الــي خفــض ضغــط الــدم.<br />&bull; أملوديبيــن ينتمــي إلــى مجموعــة مــن مــواد تســمى &quot; مناهــض أيــون الكالســيوم أو حاصــر<br />لقنــوات الكالســيوم .&quot;<br />الأملوديبيــن يعمــل علــى تثبيــط تدفــق أيونــات الكالســيوم عبــر الغشــاء إلــى داخــل العضــلات<br />الملســاء بالأوعيــة الدمويــة وعضلــة القلــب. ممــا يــؤدي الــي اســترخاء الأوعيــة الدمويــة ويقلــل<br />مــن ضغــط الــدم.<br />يســتخدم ســيفيكار لعــلاج المرضــى الذيــن لا يتــم التحكــم بضغــط الــدم عندهــم بالأولميســارتان<br />ميدوكســوميل لوحــده اوالأملوديبيــن لوحــده<br /><br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&bull; إذا كنــت تعانــي مــن فــرط الحساســية تجــاه أولميســارتان ميدوكســوميل، أو أملوديبيــن، أو<br />الديهيدروبيريدينــات؛ مجموعــة خاصــة مــن حاصــرات قنــوات الكالســيوم، أو تجــاه المكونــات<br />الأخــرى المذكــورة فــي القســم ( ٧معلومــات إضافيــة.)<br />ِ &bull; إذا كنــت حامــ ًلا ً فــي أكثــر مــن ثلاثــة أشــهر (يفضــل أيضــا عــدم تنــاول ســيفيكار فــي الأشــهر<br />الأولــى مــن الحمــل &ndash; انظــري قســم &quot;الحمــل والرضاعــة الطبيعيــة.)&quot;<br />ِ &bull; إذا كنــت ً مرضع ُ ــا أو علــى وشــك بــدء الرضاعــة الطبيعيــة. لا يوصــى بتنــاول ســيفيكار فــي<br />ُ الأمهـات الم ِ رضعـات، وقـد يختـار لـك ً طبيبـك علاج ِـا آخـر إذا كنـت ترغبيـن فـي ممارسـة الرضاعـة<br />الطبيعيــة.<br />&bull; يجـب عـدم اسـتعمال سـيفيكار مـع اليسـكارين فـي المرضـى الذيـن يعانـون مـن مـرض السـكري<br />أو الفشـل الكلـوي.<br />&bull; إذا كنـت تعانـي مـن نقـص نتـاج القلـب (انخفـاض كميـة الـدم التـي يضخهـا القلـب) ناتـج عـن<br />مشـكلة خطيـرة بالقلـب، أو نوبـة قلبيـة، أو إذا كنـت قـد عانيـت مـن نوبـة قلبيـة (احتشـاء عضلـة<br />القلـب الحـاد) خـلال الأربعـة أسـابيع الأخيـرة.<br />&bull; إذا كنـت تعانـي مـن ألـم أو شـعور بعـدم الارتيـاح بالصـدر عنـد الراحـة أو أثنـاء الليـل (ذبحـة صدريـة<br />غير مســتقرة.)<br />&bull; إذا كنت تعاني من قصور كبدي شديد وانسداد بالجهاز الصفراوي.<br />&bull; الأطفـال والمراهقـون (أقـل مـن ُ 1٨عـام)؛ لا يوصـى بتناول سـيفيكار فـي الأطفـال والمراهقين<br />الذيـن تقـل أعمارهـم عـن ً 1٨عاما.<br /><br />أخبر/استشر طبيبك قبل تناول سيفيكار في الحالات التالية:<br />- إذا كنــت تعانــي مــن حساســية (فــرط الحساســية) تجــاه أولميســارتان ميدوكســوميل، أو<br />أملوديبيــن، أو الديهيدروبيريدينــات؛ مجموعــة خاصــة مــن حاصــرات قنــوات الكالســيوم، أو تجــاه<br />المكونــات الأخــرى المذكــورة فــي القســم ( ٧معلومــات إضافيــة.)<br />- إذا كنت تعتقد بأنك تعاني من حساسية، فأخبر طبيبك قبل تناول سيفيكار.<br />ِ - إذا كنــت حامــ ًلا ً فــي أكثــر مــن ثلاثــة أشــهر. (يفضــل أيضــا عــدم تنــاول ســيفيكار فــي الأشــهر<br />الأولــى مــن الحمــل &ndash; انظــري قســم &quot;الحمــل والرضاعــة الطبيعيــة.)&quot;<br />- نظام حاصرات الرينين أنجيوتنسين ألدوستيرون (:)RAAS<br />اســتعمال دواء ســيفيكار مــع مثبطــات الإنزيــم المحــول للأنجيوتنســين، أو عقــار اليســكارين قــد<br />يسـبب مخاطـر ٳرتفـاع نسـبه البوتاسـيوم بالـدم، وتدهـور وظائـف الكلـى وانخفـاض ضغـط الـدم.<br />ولذلـك، يجـب الا تسـتعمل هـذه العقاقيـر معـا، خصوصـا فـي المرضـى الذيـن يعانـون مـن مشـاكل<br />فـي الكلـى.<br />ً - إذا كنــت تعانــي مــن مشــاكل شــديدة بالكبــد، أو إذا كان هنــاك قصــورا فــي إفــراز العصــارة<br />ً الصفراويـة أو انسـدادا فـي تصريـف العصـارة الصفراويـة مـن المـرارة (مثـل حصـوات المـرارة،) أو<br />إذا كنــت تعانــي مــن يرقــان &quot;صفــراء&quot; (اصفــرار لــون البشــرة والعينيــن.)<br />- إذا كنـت تعانـي مـن نقـص نتـاج القلـب ناتـج عـن مشـكلة خطيـرة بالقلـب، أو نوبـة قلبيـة، أو إذا<br />كنـت قـد عانيـت مـن نوبـة قلبيـة (احتشـاء عضلـة القلـب الحـاد) خـلال الأربعـة أسـابيع الأخيـرة.<br />- إذا كنـت تعانـي مـن ألـم أو شـعور بعـدم الارتيـاح بالصـدر عنـد الراحـة أو أثنـاء الليـل (ذبحـة صدريـة<br />غير مســتقرة.)<br />- إذا كنت تعاني من قصور كبدي شديد وانسداد بالجهاز الصفراوي.<br />الحمل والرضاعة الطبيعية:<br /><strong>الحمل:</strong><br />ِ يجب إبلاغ طبيبك ِ إذا كنت تعتقدين أنك حام ًلا (أو قد تصبحين حاملا.)<br />سـينصحك طبيبـك بالتوقـف عـن تنـاول سـيفيكار قبـل أن تصبحـي حامـ ًلا أو بمجـرد معرفتـك أنـك<br />حامـ ًلا ُ ، وسـينصحك بتنـاول دواء آخـر حيـث انـه لا يوصـى بتنـاول سـيفيكار فـي الأشـهر الأولـى مـن<br />الحمـل، ولا يجـب تناولـه إذا كنـت حامـلا ُ فـي أكثـر مـن ثلاثـة أشـهر، حيـث قـد ي ً لحـق ضـرر ً ا خطيـرا<br />ِ بطفلـك إذا تـم تناولـه بعـد الشـهر الثالـث مـن الحمـل. إذا أصبحـت حامـلا أثنـاء العـلاج بـ &quot;سـيفيكار،&quot;<br />ُ في ِ رجـى إخبـار طبيبـك وزيارتـه بـدون تأخيـر.<br />الرضاعة الطبيعية<br />ِ أخبـري طبيبـك ِ إذا كنـت ُم ً رضع ِـا أو كنـت ُ علـى وشـك بـدء الرضاعـة الطبيعيـة. لا يوصـى بتنـاول<br />ِ ســيفيكار فــي الأمهــات المرضعــات، وقــد يختــار لــك ِ طبيبــك ً علاج َ ــا آخــر. استشــيري الطبيــب أو<br />ِ الصيدلــي الخــاص بــك قبــل تنــاول أي دواء إذا كنــت حامــلا ُ أو م ً رضعــا.<br />حالات خاصة:<br /><strong>انخفــاض ضغــط الــدم لــدى المرضــى الذيــن يعانــون مــن نفــاذ الأمــلاح أو حجــم الســوائل<br />فــي الجســم</strong><br />ً قــد يحــدث انخفــاض فــي ضغــط الــدم مصحوبــا بأعــراض بعــد بــدء العــلاج بأولميســارتان<br />ميدوكسـوميل. قـد يكـون المرضـى الذيـن لديهـم نظـام رينين-أنجيوتنسـين نشـط، مثـل المرضـى<br />الذيـن يعانـون مـن نفـاذ الأمـلاح و/أو حجـم السـوائل فـي الجسـم (علـى سـبيل المثـال المرضـى<br />الذيــن يتــم علاجهــم بجرعــات عاليــة مــن الأدويــة المــدرة للبــول،) معرضــون لذلــك بشــكل خــاص.<br />يجـب بـدأ العـلاج بــ &quot;سـيفيكار&quot; تحـت إشـراف طبـي دقيـق. إذا حـدث انخفـاض فـي ضغـط الـدم،<br />فــلا بــد مــن وضــع المريــض فــي وضعيــة الاســتلقاء وإعطائــه محلــول ملحــي عــادي عــن طريــق<br />التسـريب فـي الوريـد إذا لـزم الأمـر. لا يعـد حـدوث انخفـاض ضغـط الـدم بشـكل عابـر مـن موانـع<br />الاســتمرار فــي العــلاج، حيــث عــادة مــا يمكــن أن يســتمر العــلاج بــدون أيــة صعوبــات بمجــرد أن<br />يسـتقر ضغـط الـدم.<br />ضيق شديد في الصمام الأورطي<br />مثلمـا يحـدث مـع أي مـن موسـعات الشـرايين الطرفيـة الأخـرى، يجـب توخـي الحـذر عنـد تنـاول<br />ســيفيكار، خاصــة فــي المرضــى الذيــن يعانــون مــن ضيــق شــديد فــي الصمــام الأورطــي، علــى<br />الرغــم مــن أنــه تــم الإبــلاغ فــي حــالات نــادرة عــن حــدوث انخفــاض حــاد فــي ضغــط الــدم بعــد<br />تنــاول الــدواء عــن طريــق الفــم.<br />َّ المرضــى الذيــن يعانــون مــن انســداد شــديد فــي الشــريان التاجــي (مــرض انســدادي<br /><strong>بالشــريان التاجــي)</strong><br />َّ قــد يعانــي المرضــى، خاصــة المرضــى الذيــن يعانــون مــن انســداد شــديد فــي الشــريان التاجــي،<br />مـن زيـادة معـدل تكـرار أو مـدة أو شـدة الذبحـة الصدريـة أو احتشـاء عضلـة القلـب الحـاد عنـد بـدء<br />العـلاج بحاصـرات قنـوات الكالسـيوم أو عنـد زيـادة الجرعـة. لـم تتضـح آليـة هـذا التأثيـر.<br />المرضى الذين يعانون من هبوط &quot;فشل&quot; القلب الاحتقاني<br />بوجـه عـام، يجـب اسـتخدام حاصـرات قنـوات الكالسـيوم بحـذر فـي المرضـى الذيـن يعانـون مـن<br />هبـوط القلـب. علـى الرغـم مـن أنـه لـم يكـن هنـاك دليـل علـى تفاقـم هبـوط القلـب فـي التجـارب<br />ً الســريرية التــي تــم إجراؤهــا بواســطة أملوديبيــن وذلــك اســتنادا إلــى معاييــر تحمــل ممارســة<br />التماريـن، ولـم يكـن هنـاك أثـر جانبـي عـام علـى فتـرة البقـاء علـى قيـد الحيـاة أو معـدل حـدوث<br />أمــراض القلــب (كمــا تــم تحديــده بواســطة اضطــراب النظــم القلبــي المهــدد للحيــاة، أو احتشــاء<br />عضلــة القلــب الحــاد أو دخــول المستشــفى نتيجــة تفاقــم هبــوط القلــب.)<br />المرضى الذين يعانون من قصور وظائف الكلى<br />ُي ُ توقــع حــدوث تغييــرات فــي وظائــف الكلــى لــدى الأفــراد الأكثــر عرضــة والذيــن يتــم علاجهــم<br />ً بأولميسـارتان ميدوكسـوميل وذلـك يكـون ناتج َـا عـن تثبيـط نظـام الرينين-أنجيوتنسين-أْلدوسـتيرون.<br />فـي المرضـى الذيـن قـد تعتمـد وظائـف الكلـى لديهـم علـى نشـاط نظـام الرينين-أنجيوتنسـين-<br />َأْلدوسـتيرون (مثـل المرضـى الذيـن يعانـون مـن هبـوط القلـب الاحتقانـي الشـديد،) ارتبـط العـلاج<br />بمثبطــات الإنزيــم المحــول لهرمــون الأنجيوتنســين وحاصــرات مســتقبل هرمــون الأنجيوتنســين<br />بحـدوث انخفـاض فـي كميـة البـول (قلـة البـول) أو آزوتيميـة متقدمـة (ارتفـاع نسـبة المركبـات<br />ُ التـي تحتـوي علـى النيتروجيـن فـي الـدم) وارتبـط (فـي حـالات نـادرة) بحـدوث فشـل ك ٍّ لـوي حـاد<br />و/أو الوفـاة. قـد تحـدث اعـراض مشـابهة لـدى المرضـى الذيـن يتـم علاجهـم بــ &quot;سـيفيكار&quot; وذلـك<br />لوجـود أولميسـارتان ميدوكسـوميل بـه.<br />المرضى الذين يعانون من قصور وظائف الكبد<br />ً نظـرا لاسـتقلاب الأملوديبيـن بدرجـة كبيـرة عـن طريـق الكبـد، وبلـوغ العمـر النصفـي للإزالـة مـن<br />البلازمــا ( ٥٦ )t1/2ســاعة فــي المرضــى الذيــن يعانــون مــن قصــور شــديد فــي وظائــف الكبــد،<br />فيجــب توخــي الحــذر عنــد إعطــاء ســيفيكار للمرضــى الذيــن يعانــون مــن قصــور شــديد بوظائــف<br />الكبــد.<br />المرضى من كبار السن<br />فـي المرضـى الذيـن تتعـدى أعمارهـم ً ٦٥عامـا، سـيفحص الطبيـب ضغـط الـدم بصـورة منتظمـة<br />عنـد أيـة زيـادة للجرعـة؛ للتأكـد مـن عـدم انخفـاض ضغـط الـدم بشـكل شـديد.<br />المرضى ذوي البشرة السمراء<br />كمـا هـو الحـال مـع بعـض الأدويـة المشـابهة الأخـرى، قـد يكـون تأثيـر سـيفيكار الخافـض لضغـط<br />الـدم أقـل إلـى حـد مـا فـي المرضـى ذوي البشـرة السـمراء.<br />القيادة واستخدام الآلات<br />قـد تشـعر بنعـاس أو دوخـة أثنـاء عـلاج ارتفـاع ضغـط الـدم الـذي تعانـي منـه. إذا حـدث ذلـك، فـلا<br />تمـارس القيـادة، ولا تسـتخدم الآلات حتـى تـزول تلـك الأعـراض. استشـر طبيبـك.<br />ٍّ أخبر طبيبك إذا كنت تعاني من أي من المشاكل الصحية التالية:<br />- مشاكل في الكلى، أو زراعة كلى.<br />- مرض بالكبد.<br />- هبوط القلب، أو مشاكل في صمامات أو عضلة القلب.<br />ً - قـيء شـديد، أو إسـهال، أو إذا كنـت تتنـاول علاجـا بجرعـات مرتفعـة مـن الأدويـة المـدرة للبـول،<br />ً أو إذا كنـت تتبـع نظام ًّـا غذائيـا قليـل الملـح.<br />- ارتفاع مستويات البوتاسيوم في الدم لديك.<br />- مشاكل في الغدد الكظرية (غدد تنتج هرمونات وتوجد فوق الكليتين.)<br />ُ - كمـا هـو الحـال مـع أي دواء خافـض لضغـط الـدم، قـد يـؤدي انخفـاض ضغـط دم بشـكل مفـرط<br />فـي المرضـى الذيـن يعانـون مـن اضطرابـات تدفـق الـدم إلـى القلـب أو المـخ إلـى حـدوث نوبـة<br />قلبيـة أو سـكتة دماغيـة. ولـذا سـيقوم طبيبـك بالتحقـق مـن ضغـط الـدم لديـك بعنايـة.<br />تناول أدوية أخرى<br />ُيرجـى إبـلا ً غ الطبيـب، أو الصيدلـي الخـاص بـك إذا كنـت تتنـاول أو تناولـت مؤخـر ًّ ا أيـا مـن الأدويـة<br />التالية:<br />- حاصــرات الرينيــن أنجيوتنســين الألدوســتيرون المــزدوج، يمنــع اســتخدام ســيفيكار مــع<br />عقــار اليســكارين او مثبطــات الإنزيــم المحــول للأنجيوتنســين أو غيرهــا مــن موانــع مســتقبلات<br />الأنجيوتنســين فــي المرضــى الذيــن يعانــون مــن مــرض الســكري أو الفشــل الكلــوي.<br />- يجـب عـدم اسـتعمال حاصـرات رينيـن انجيوتنسـين المـزدوج (مثـالا مـع مثبطـات الإنزيـم المحـول<br />للأنجيوتنسـين لـدواء سـيفيكار،) وخاصـة فـي المرضـى الذيـن يعانـون مـن مشـاكل فـي الكلـى.<br />- مكمــلات غذائيــة تحتــوي علــى البوتاســيوم، أو بدائــل ملــح تحتــوي علــى البوتاســيوم، أو<br />ُ أدويــة مــدرة للبــول، أو الهيباريــن (يســتخدم لزيــادة ســيولة الــدم ومنــع تكــون جلطــات الــدم.)<br />قـد يـؤدي اسـتخدام هـذه الأدويـة فـي نفـس وقـت اسـتخدام سـيفيكار إلـى ارتفـاع مسـتويات<br />البوتاســيوم فــي الــدم.<br />- الليثيــوم ُ (دواء يســتخدم لعــلاج التقلبــات المزاجيــة وبعــض أنــواع الاكتئــاب،) قــد يــؤدي<br />اسـتخدامه فـي نفـس وقـت اسـتخدام سـيفيكار إلـى زيـادة التسـمم الناتـج عـن الليثيـوم. إذا كان<br />ينبغــي عليــك تنــاول الليثيــوم، فســيقوم طبيبــك بقيــاس مســتويات الليثيــوم فــي الــدم لديــك.<br />- مضــادات الالتهــاب غيــر الســتيرويدية &quot;( ،&quot; ُ NSAIDsأدويــة تســتخدم لتخفيــف الآلام، والتــورم،<br />وأعـراض الالتهـاب الأخـرى، بمـا فـي ذلـك التهـاب المفاصـل،) قـد يـؤدي اسـتخدامها فـي نفـس<br />وقـت اسـتخدام سـيفيكار إلـى زيـادة خطـر حـدوث فشـل كلـوي. قـد تقلـل مضـادات الالتهـاب غيـر<br />السـتيرويدية مـن تأثيـر سـيفيكار.<br />- أدوية أخرى خافضة لضغط الدم، حيث قد يتم زيادة تأثير سيفيكار.<br />- بعــض مضــادات الحموضــة (علاجــات عســر الهضــم أو الحموضــة،) حيــث قــد ينخفــض تأثيــر<br />ســيفيكار بشــكل طفيــف.<br />- الأدويــة المســتخدمة لعــلاج فيــروس نقــص المناعــة البشــري/متلازمة نقــص المناعــة<br /><strong>المكتســب &quot;الإيــدز&quot; </strong>(مثــل ريتونافيــر) أو لعــلاج العــدوى الفطريــة (مثــل كيتوكونــازول<br />وإيتراكونــازول).<br />يم ُ ، دواء يستخدم لعلاج المشاكل المتعلقة بنظم القلب، وارتفاع ضغط الدم.<br />ِ<br />- ِ ديلتياز<br />- مضــادات التشــنجات ُ والتــي تســتخدم لعــلاج الصــرع (مثــل: كاربامازيبيــن، وفينوباربيتــال،<br />وفينيتويــن، وفوســفنتوين، وبريميــدون.)<br />- ريفامبيسين، ُ دواء يستخدم لعلاج الدرن (مرض السل،) وأنواع أخرى من العدوى.<br />- نبتة سانت جونز (هايبريكم برفوراتم،) وهي عبارة عن علاج عشبي.<br />- سـيلدينافيل ُ ، دواء يسـتخدم لعـلاج عـدم القـدرة علـى الانتصـاب أو للحفـاظ عليـه، حيـث قـد يزيـد<br />مـن التأثيـر الخافـض لضغـط الـدم.<br /><strong>ُيرجــى إبــلا ً غ الطبيــب أو الصيدلــي الخــاص بــك إذا كنــت تتنــاول أو تناولــت مؤخــرا أيــة</strong><br /><strong>أدويــة أخــرى، بمــا فيهــا الأدويــة التــي يتــم الحصــول عليهــا بــدون وصفــة طبيــة.</strong><br /><br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>ً تناول دائما سيفيكار كما أخبرك طبيبك بالضبط. ً إذا لم تكن متأكدا من كيفية التناول، يجب عليك<br />مراجعة الطبيب أو الصيدلي الخاص بك.<br />الجرعة الموصى بها من سيفيكار هي حبة واحدة في اليوم مع الطعام أو بدونه.<br />ابتلع الأقراص مع بعض السوائل (على سبيل المثال كوب من الماء)<br />لا تمضغ الأقراص ولا تأخذها مع عصير الجريب فروت .<br />حاول ان تتناول الأقراص يوميا في نفس الوقت، على سبيل المثال في وقت الإفطار<br />تتحقق الآثار الخافضة للضغط كحد أقصى في غضون أسبوعين بعد تغيير الجرعة.<br />إذا تناولت كمية من سيفيكار أكثر مما يجب<br />إذا تناولت كمية من سيفيكار أكثر مما يجب قد يحدث لك انخفاض في ضغط الدم مع أعراض<br />مثل الدوخة، وسرعة أو بطء ضربات القلب، أخبر الطبيب الخاص بك، أو اذهب إلى أقرب<br />مستشفى على الفور. خذ العبوة وأي أقراص متبقية من سيفيكار او هذه النشرة معك حتى<br />يتسنى للأطباء معرفة ما تناولته.<br />َ قد يتراكم سائل زائد في رئتيك (و َذ َم ٌة ِر َئ ِو َّية) مما يسبب ضيق التنفس الذي قد يظهر في غضون<br />٤٨-٢٤ساعة بعد الاستهلاك<br />إذا نسيت أن تتناول سيفيكار<br />إذا نسيت تناول إحدى الجرعات، فتناولها بمجرد تذكرك لها، إلا إذا كان قد حان موعد الجرعة<br />التالية. لا تتناول جرعة مضاعفة.<br />إذا توقفت عن تناول سيفيكار<br />استمر في تناول سيفيكار، ما لم يخبرك طبيبك بتوقفه.<br />إذا كانت لديك أية أسئلة إضافية حول استخدام هذا الدواء، فاستشر الطبيب أو الصيدلي<br /><strong>الخاص بك.</strong><br /><br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>الأثريــن الجانبييــن التالييــن قــد يكونــان خطيريــن، علــى الرغــم مــن عــدم حدوثهمــا لــدي<br /><strong>الكثيــر مــن الأشــخاص:</strong><br />&bull; قــد تحــدث تفاعــلات حساســية مصحوبــة بتــورم الوجــه، الفــم و/أو الحنجــرة مــع حكــة وطفــح<br />جلــدي أثنــاء العــلاج بــ &quot;ســيفيكار.&quot; إذا حــدث ذلــك، فتوقــف عــن تنــاول ســيفيكار وأخبــر طبيبــك<br />علــى الفــور.<br />&bull; ُ يمكــن أن ي ً ســبب ســيفيكار انخفاض ً ــا شــديد ًّ ا جــدا فــي ضغــط الــدم فــي الأفــراد الأكثــر عرضــة<br />ُ لذلــك. قــد ي ً ســبب ذلــك دوار ً ا شــديدا، أو إغمــاء. إذا حــدث ذلــك، فيجــب أن تتوقــف عــن تنــاول<br />ً ســيفيكار، وأن تخبــر طبيبــك علــى الفــور، وأن تســتلقي فــي الوضــع راقــدا.<br />الاعراض الجانبية المحتملة الأخرى لـ &quot;سيفيكار:&quot;<br /><strong>- ُ شائعة (تؤثر على أقل من مريض واحد من كل 10مرضى:)</strong><br />دوخة، وصداع، وتورم الكاحلين أو القدمين أو الساقين أو اليدين أو الذراعين، وإجهاد.<br /><strong>- ُ غير شائعة (تؤثر على أقل من مريض واحد من كل 100مريض:)</strong><br />دوخــة عنــد الوقــوف، وفقــدان الطاقــة، وتنميــل أو وخــز فــي اليديــن أو القدميــن، ودوار،<br />وضربـات قلـب قويـة، وتسـارع ضربـات القلـب، وانخفـاض ضغـط الـدم المصحـوب بأعـراض مثـل<br />الدوخـة والـدوار، وصعوبـة التنفـس، وسـعال، وغثيـان، وقـيء، وعسـر هضـم، وإسـهال، وإمسـاك،<br />وجفـاف الفـم، وألـم فـي الجـزء العلـوي مـن البطـن، وطفـح جلـدي، وتقلصـات عضليـة، وألـم<br />فـي الذراعيـن والسـاقين، وألـم فـي الظهـر، والشـعور برغبـة شـديدة للتبـول، وخمـول جنسـي<br />(قلــة النشــاط الجنســي،) وعــدم القــدرة علــى الحصــول علــى الانتصــاب أو الحفــاظ عليــه،<br />ُ وضعـف. كمـا ل ً وحظـت أيضـا بعـض التغييـرات فـي نتائـج اختبـار الـدم، وتتضمـن مـا يلـي: ارتفـاع<br />وكذلــك انخفــاض مســتويات البوتاســيوم فــي الــدم، ارتفــاع مســتويات الكرياتنيــن فــي الــدم،<br />ارتفـاع مسـتويات حمـض اليوريـك، ارتفاعـات فـي نتائـج اختبـار وظائـف الكبـد (مسـتويات إنزيـم<br />ناقلــة الجامــا جلوتاميــل.)<br /><strong>- ُ نادرة (تؤثر على أقل من مريض واحد من كل ٍ 1000مريض:)</strong><br />فرط الحساسية تجاه الدواء، وإغماء، وطفح جلدي مصحوب بشرى (ارتكاريا،) وتورم الوجه.<br /><strong>- غير معروف لا يمكن تقدير معدل الحدوث من البيانات المتاحة:</strong><br />إذا كنـت تعانـي مـن اصفـرار بيـاض العيـن، والبـول الداكـن، وحكـة فـي الجلـد، حتـى لـو كنـت<br />بـدأت العـلاج بسـيفيكار منـذ فتـرة طويلـة، فاتصـل بطبيبـك علـى الفـور الـذي سـيقيم أعراضـك<br />ويقـرر كيفيـة متابعـة الـدم دواء الضغـط.<br />تـم الإبـلاغ عـن أعـراض جانبيـة أخـرى مـع تنـاول أولميسـارتان ميدوكسـوميل أو أملوديبيـن<br /><strong>بمفردهمـا، وهـي:</strong><br />- الأعراض الجانبية الناتجة عن تناول أولميسارتان ميدوكسوميل<br />ذبحـة (ألـم، أو شـعور بعـدم الارتيـاح بالصـدر، يعـرف باسـم الذبحـة الصدريـة،) والتهـاب الشـعب<br />الهوائيــة، والتهــاب الحلــق، ورشــح أو انســداد الأنــف، وألــم فــي البطــن، وألــم فــي المعــدة،<br />وألــم فــي المفاصــل أو العظــام، ووجــود دم فــي البــول، وعــدوى المســالك البوليــة، وألــم<br />فـي الصـدر، وأعـراض شـبيهة بالأنفلونـزا، وألـم، وتغييـرات فـي نتائـج اختبـار الـدم مثـل ارتفـاع<br />مسـتويات الدهـون (فـرط الدهـون الثلاثيـة فـي الـدم،) وارتفـاع فـي نتائـج اختبـارات وظائـف<br />الكبــد والعضــلا ً ت، هنــاك أيض ً ــا أعراضــا جانبيــة إضافيــة، تحــدث جميعهــا بمعــدل تكــرار نــادرا<br />ًّ جــد ُ ا: انخفــاض عــدد أحــد أنــواع خلايــا الــدم، ي ُ عــرف باســم الصفائــح الدمويــة، ممــا قــد يــؤدي<br />إلـى سـهولة التكـدم، أو إطالـة وقـت النزيـف، وحكـة، وظواهـر جلديـة (طفـح جلـدي ظاهـر،)<br />وتــورم اللســان أو الوجــه، وطفــح جلــدي تحسســي، وألــم بالعضــلات، قصــور كلــوي وفشــل<br />كلـوي حـاد، وزيـادة اليوريـا فـي الـدم، الشـعور بأنـك لسـت علـى مـا يـرام. وفـي المرضـى كبـار<br />السـن زاد معـدل تكـرار حـدوث انخفـاض ضغـط الـدم المسـبب للـدوار الشـديد أو الإغمـاء بشـكل<br />طفيــف؛ لينتقــل مــن الاعــراض الجانبيــة النــادرة إلــى الاعــراض الجانبيــة غيــر الشــائعة.<br />- الاعراض الجانبية الناتجة عن تناول أملوديبين<br />شــعور بــدفء واحمــرار الوجــه، وألــم فــي البطــن، وانخفــاض عــدد خلايــا الــدم البيضــاء، ممــا<br />قــد يزيــد مــن خطــر حــدوث العــدوى، وانخفــاض عــدد الصفائــح الدمويــة، وتضخــم الثــدي فــي<br />الرجــال، وارتفــاع مســتوى الجلوكــوز فــي الــدم، واضطــراب النــوم، وتهيــج، واكتئــاب، وارتبــاك،<br />ً وتغييـرات مزاجيـة تتضمـن شـعورا بالقلـق، والشـعور بأنـك لسـت علـى مـا يـرام، ورعشـة، وزيـادة<br />التعــرق، وتغييــرات فــي التــذوق، وتنميــل أو وخــز فــي اليديــن أو القدميــن، واضطرابــات فــي<br />الرؤيــة، وطنيــن، وألــم فــي الصــدر، وتفاقــم الذبحــة (ألــم أو شــعور بعــدم الارتيــاح بالصــدر،)<br />والتهــاب الأوعيــة الدمويــة، ورشــح أو انســداد الأنــف، وزيــادة ســمك اللثــة، والتهــاب جــدار<br />المعـدة، وارتفـاع مسـتويات إنزيمـات الكبـد، واصفـرار لـون البشـرة والعينيـن، والتهـاب الكبـد أو<br />البنكريـاس، وظواهـر جلديـة (طفـح جلـدي ظاهـر،) وحكـة، وتسـاقط الشـعر، وتغيـر لـون الجلـد،<br />وجـود بقـع أرجوانيـة علـى الجلـد نتيجـة لنـزف بسـيط (فرفريـة،) وحـالات فرديـة مـن تفاعـلات<br />حساســية (حكــة، وطفــح جلــدي، وتــورم الوجــه، الفــم و/أو الحنجــرة، حــالات حساســية أخــرى<br />مصحوبـة بالتهـاب وتقشـر الجلـد، وتكـون فـي بعـض الأحيـان مهـددة للحيـاة،) وألـم بالعضـلات<br />أو بالمفاصـل، وزيـادة أو انخفـاض الـوزن. تـم الإبـلاغ عـن حـالات فرديـة مـن نوبـات قلبيـة وعـد<br />انتظـام ضربـات القلـب، وذبحـة فـي المرضـى الذيـن يعانـون مـن أحـد أمـراض الشـريان التاجـي،<br />ولكــن لــم يتــم التحقــق مــن وجــود علاقــة واضحــة بيــن حدوثهــا وبيــن تنــاول أملوديبيــن.<br />ٌّ إذا أصبـح أي ً مـن الاعـراض الجانبيـة خطيـرا، أو إذا لاحظـت أيـة أعـراض جانبيـة غيـر المدرجـة<br /><strong>ُ فـي هـذه النشـرة، فيرجـى إبـلاغ الطبيـب أو الصيدلـي الخـاص بـك</strong>.<br /><br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>ّ يحفظ بعيدا عن متناول و رؤية الأطفال.<br />يحفظ فى درجة حرارة أقل من 30درجة مئوية.<br />لا تستخدم سيفيكار بعد انتهاء تاريخ الصلاحية المدون على العبوة أو على الملصق.<br /><br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>&bull; المــادة الفعالــة</strong> هــي أملوديبيــن بيســلات بجرعــة تعــادل 5أو 10ملــج وأولميســارتان<br />ميدوكســوميل بجرعــة تعــادل 20أو 40ملــج<br /><strong>&bull; المكونــات الأخــرى</strong> هــي سيلســيفايد ميكروكريســتالين ســيلليولوز ، نشــا ، وكــروس كارميلــوز<br />الصوديــوم، وســتيرات الماغنســيوم. أوبــادري أبيــض (ســيفيكار&reg; ٢0\٥ملــج،) أوبــادري أصفــر<br />(ســيفيكار&reg; ٤0\٥ملــج،) أوبــادري برتقالــي (ســيفيكار&reg; ٢0\10ملــج،) أوبــادري أحمــر (ســيفيكار&reg;<br />٤0\10ملــج.)<br /><br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p><strong>أقـراص سـيفيكار&reg; 20\5ملـج</strong> هـي أقـراص دائريـة مغلفـة، بيضـاء اللـون، منقـوش عليهـا 311<br />مـن احـد الوجهيـن، تحتـوي العبـوة علـى ً ٢٨قرصـا مغلفـا.<br /><strong>أقــراص ســيفيكار&reg; 20\10ملــج</strong> هــي أقــراص دائريــة مغلفــة، برتقاليــة مائلــة إلــى الرمــادي،<br />منقــوش عليهــا 275مــن احــد الوجهيــن، تحتــوي العبــوة علــى ً ٢٨قرصــا مغلفــا.<br /><strong>أقــراص ســيفيكار&reg; 40\5ملــج </strong>هــي أقــراص دائريــة مغلفــة، كريمــي اللــون، منقــوش عليهــا<br />277مــن احــد الوجهيــن، تحتــوي العبــوة علــى ً ٢٨قرصــا مغلفــا.<br /><strong>أقـراص سـيفيكار&reg; 40\10ملـج</strong> هـي أقـراص دائريـة مغلفـة، احمـر مائـل إلـى البنـي، منقـوش<br />عليهـا 273مـن احـد الوجهيـن، تحتـوي العبـوة علـى ً ٢٨قرصـا مغلفـا.<br /><br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>ساجا الصيدلانية<br />الشركة العربية السعودية اليابانية للمنتجات الصيدلانية المحدودة<br />جدة &ndash; المملكة العربية السعودية<br />بترخيص من<br /><strong>شركة دايشي سانكيو المحدودة, طوكيو-اليابان<br />ُ للحصول على أية معلومات حول هذا الدواء، يرجى الاتصال بـ</strong><br />ساجا الصيدلانية<br />جدة &ndash; المملكة العربية السعودية<br />صندوق بريد: ،٤٢٦00جدة ،٢1٥٥1المملكة العربية السعودية<br />+9٦٦1٢٦0٦٦٦٦٧ :هاتف<br />sajapharma.com<br />تمت آخر مراجعة لهذه النشرة في {اغسطس/2023إصدار رقم {}00<br /><strong>-للإبلاغ عن أية آثار جانبية</strong><br /><strong>&bull; المملكة العربية السعودية</strong><br />- المركز الوطني للتيقظ والسلامة الدوائية<br />- مركز اتصالات الهيئة العامة للغذاء والدواء السعودية : 19999<br />npc.drug@sfda.gov.sa :- البريد الإلكتروني<br />https://ade.sfda.gov.sa :- الموقع الإلكتروني<br /><strong>&bull; دول الخليج الأخرى/ الدول الأخرى</strong><br />- الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة<br /><br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            اغسطس/2023
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sevikar 20 mg/5 mg film-coated tablets 
Sevikar 20 mg/10 mg film-coated tablets 
Sevikar 40 mg/5 mg film-coated tablets 
Sevikar 40 mg/10 mg film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sevikar 20 mg/5 mg film-coated tablets:
 
Each film-coated tablet of Sevikar contains 20 mg of olmesartan medoxomil and 5 mg of amlodipine (as amlodipine besilate).
Sevikar 20 mg/5 mg film-coated tablets:
Each film-coated tablet of Sevikar contains 20 mg of olmesartan medoxomil and 10 mg of amlodipine (as amlodipine besilate).
Sevikar 40 mg/5 mg film-coated tablets:
Each film-coated tablet of Sevikar contains 40 mg of olmesartan medoxomil and 5 mg of amlodipine (as amlodipine besilate).
Sevikar 40 mg/10 mg film-coated tablets:
Each film-coated tablet of Sevikar contains 40 mg of olmesartan medoxomil and 10 mg of amlodipine (as amlodipine besilate).
For a full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet
Sevikar 20 mg/5 mg film-coated tablets:
White round film coated tablets coded by 311 on one side plain on the other side.
Sevikar 20 mg/10 mg film-coated tablets:
Grayish orange round film coated tablets coded by 275 on one side plain on the other side.
Sevikar 40 mg/5 mg film-coated tablets:
Creamy round film coated tablets coded by 277 on one side plain on the otherside.
Sevikar 40 mg/10 mg film-coated tablets:
Brownish red round film coated tablets coded by 273 on one side plain on the other side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sevikar is indicated for the treatment of hypertension, alone or with other antihypertensive agents</p><p>Sevikar is indicated in adult patients whose blood pressure is not adequately controlled on olmesartan medoxomil or amlodipine monotherapy (see section 4.2 and section 5.1).</p><p>Sevikar may also be used as initial therapy in patients who are likely to need multiple antihypertensive agents to achieve their blood pressure goals.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>1.1&nbsp;&nbsp; Adults</p><p>The recommended dosage of Sevikar is 1 tablet per day.</p><p>Sevikar 20 mg/5 mg may be administered in patients whose blood pressure is not adequately controlled by 20 mg olmesartan medoxomil or 5 mg amlodipine alone.</p><p>Sevikar 20 mg/10 mg may be administered in patients whose blood pressure is not adequately controlled by 20 mg olmesartan medoxomil or 10 mg amlodipine alone. Sevikar 40 mg/5 mg may be administered in patients whose blood pressure is not adequately controlled by Sevikar 20 mg/5 mg.</p><p>Sevikar 40 mg/10 mg may be administered in patients whose blood pressure is not adequately controlled by Sevikar 40 mg/5 mg.</p><p>&nbsp;</p><p>A step-wise titration of the dosage of the individual components is recommended before changing to the fixed combination. When clinically appropriate, direct change from monotherapy to the fixed combination may be considered.</p><p>For convenience, patients receiving olmesartan medoxomil and amlodipine from separate tablets may be switched to Sevikar tablets containing the same component doses.</p><p>Sevikar can be taken with or without food.</p><p>Elderly (age 65 years or over)</p><p>No adjustment of the recommended dose is generally required for elderly patients but increase of the dosage should take place with care (see sections 4.4 and 5.2).</p><p>If up-titration to the maximum dose of 40 mg olmesartan medoxomil daily is required, blood pressure should be closely monitored.</p><p>Renal impairment</p><p>The maximum dose of olmesartan medoxomil in patients with mild to moderate renal impairment (creatinine clearance of 20 &ndash; 60 mL/min) is 20 mg olmesartan medoxomil once daily, owing to limited experience of higher dosages in this patient group. The use of Sevikar in patients with severe renal impairment (creatinine clearance &lt; 20 mL/min) is not recommended (see 4.4, 5.2).</p><p>Monitoring of potassium levels and creatinine is advised in patients with moderate renal impairment.</p><p>Hepatic impairment</p><p>Sevikar should be used with caution in patients with mild to moderate hepatic impairment (see sections 4.4, 5.2).</p><p>In patients with moderate hepatic impairment, an initial dose of 10 mg olmesartan medoxomil once daily is recommended and the maximum dose should not exceed 20 mg once daily. Close monitoring of blood pressure and renal function is advised in hepatically-impaired patients who are already receiving diuretics and/or other antihypertensive agents. There is no experience of olmesartan medoxomil in patients with severe hepatic impairment.</p><p>As with all calcium antagonists, amlodipine&#39;s half-life is prolonged in patients with impaired liver function and dosage recommendations have not been established. Sevikar should therefore be administered with caution in these patients. The pharmacokinetics of amlodipine have not been studied in severe hepatic impairment. Amlodipine should be initiated at the lowest dose and titrated slowly in patients with impaired liver function. Use of Sevikar in patients with severe hepatic impairment is contraindicated (see section 4.3).</p><p>Paediatric population</p><p>The safety and efficacy of Sevikar in children and adolescents below 18 years has not been established. No data are available.</p><p>Method of administration:</p><p>The tablet should be swallowed with a sufficient amount of fluid (e.g. one glass of water). The tablet should not be chewed and should be taken at the same time each day.</p><p>Black Patients</p><p>Of the total number of subjects in the double-blind clinical study of Sevikar, 25% (481/1940) were black patients. Sevikar was effective in treating black patients</p><p>&nbsp;</p><p>(usually a low-renin population), and the magnitude of blood pressure reduction in black patients approached that observed for non-black patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substances, to dihydropyridine derivatives or to any of the excipients (see section 6.1).
Second and third trimesters of pregnancy (see sections 4.4 and 4.6). Severe hepatic insufficiency and biliary obstruction (see section 5.2).
Due to the component amlodipine Sevikar is also contraindicated in patients with:
-	severe hypotension.
-	shock (including cardiogenic shock).
-	obstruction of the outflow tract of the left ventricle (e.g. high grade aortic stenosis).
-	haemodynamically unstable heart failure after acute myocardial infarction
Sevikar should not be co-administered with aliskiren in patients with diabetes mellitus or renal impairment

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>1.1&nbsp;&nbsp; Patients with hypovolaemia or sodium depletion:</p><p>Symptomatic hypotension may occur in patients who are volume and/or sodium depleted by vigorous diuretic therapy, dietary salt restriction, diarrhoea or vomiting, especially after the first dose. Correction of this condition prior to administration of Sevikar or close medical supervision at the start of the treatment is recommended. Other conditions with stimulation of the renin-angiotensin-aldosterone system:</p><p>In patients whose vascular tone and renal function depend predominantly on the activity of the renin-angiotensin-aldosterone system (e.g. patients with severe congestive heart failure or underlying renal disease, including renal artery stenosis), treatment with other medicinal products that affect this system, such as angiotensin II receptor antagonists, has been associated with acute hypotension, azotaemia, oliguria or, rarely, acute renal failure.</p><p>Dual Blockade of the Renin-Angiotensin-aldosterone System (RAAS):</p><p>Combination of Sevikar with ACE inhibitors, or aliskiren may cause increased risks of hyperkalemia, worsening of kidney function and hypotension. Therefore, this combination should not be used, especially in patients with kidney problems.</p><p>Renovascular hypertension:</p><p>There is an increased risk of severe hypotension and renal insufficiency when patients with bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney are treated with medicinal products that affect the renin- angiotensin- aldosterone system.</p><p>Renal impairment and kidney transplantation:</p><p>When Sevikar is used in patients with impaired renal function, periodic monitoring of serum potassium and creatinine levels is recommended. Use of Sevikar is not recommended in patients with severe renal impairment (creatinine clearance &lt; 20 mL/min) (see sections 4.2, 5.2). There is no experience of the administration of Sevikar in patients with a recent kidney transplant or in patients with end-stage renal impairment (i.e. creatinine clearance &lt; 12 mL/min).</p><p>Hepatic impairment:</p><p>Exposure to amlodipine and olmesartan medoxomil is increased in patients with hepatic impairment (see section 5.2). Care should be taken when Sevikar is administered in patients with mild to moderate hepatic impairment. In moderately</p><p>&nbsp;</p><p>impaired patients, the dose of olmesartan medoxomil should not exceed 20 mg (see section 4.2). In patients with impaired hepatic function, amlodipine should be initiated at the lower end of the dosing range and caution should be used, both on initial treatment and when increasing the dose. Use of Sevikar in patients with severe hepatic impairment is contraindicated (see section 4.3).</p><p>Hyperkalaemia:</p><p>As with other angiotensin II antagonists and ACE inhibitors, hyperkalaemia may occur during treatment, especially in the presence of renal impairment and/or heart failure (see section 4.5). Close monitoring of serum potassium levels in at-risk patients is recommended.</p><p>Concomitant use with potassium supplements, potassium-sparing diuretics, salt substitutes containing potassium, or other medicinal products that may increase potassium levels (heparin, etc.) should be undertaken with caution and with frequent monitoring of potassium levels.</p><p>Lithium:</p><p>As with other angiotensin II receptor antagonists, the concomitant use of Sevikar and lithium is not recommended (see section 4.5).</p><p>Aortic or mitral valve stenosis; obstructive hypertrophic cardiomyopathy:</p><p>Due to the amlodipine component of Sevikar, as with all other vasodilators, special caution is indicated in patients suffering from aortic or mitral valve stenosis, or obstructive hypertrophic cardiomyopathy.</p><p>Primary aldosteronism:</p><p>Patients with primary aldosteronism generally will not respond to antihypertensive medicinal products acting through inhibition of the renin-angiotensin system. Therefore, the use of Sevikar is not recommended in such patients.</p><p>Heart failure:</p><p>As a consequence of the inhibition of the renin-angiotensin-aldosterone system, changes in renal function may be anticipated in susceptible individuals. In patients with severe heart failure whose renal function may depend on the activity of the renin-angiotensin-aldosterone system, treatment with angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor antagonists has been associated with oliguria and/or progressive azotaemia and (rarely) with acute renal failure and/or death.</p><p>Calcium channel blockers, like amlodipine in Sevikar, should be used with caution in patients with heart failure, as they may increase the risk of future cardiovascular events and mortality. In a long-term, placebo controlled study of amlodipine in patients with severe heart failure (NYHA III and IV), the reported incidence of pulmonary oedema was higher in the amlodipine group than in the placebo group (see section 5.1).</p><p>Ethnic differences:</p><p>As with all other angiotensin II antagonists, the blood pressure lowering effect of Sevikar can be somewhat less in black patients than in non-black patients, possibly because of a higher prevalence of low-renin status in the black hypertensive population.</p><p>Elderly patients</p><p>In the elderly, increase of the dosage should take place with care (see section 5.2). Pregnancy:</p><p>&nbsp;</p><p>Angiotensin II antagonists should not be initiated during pregnancy. Unless continued angiotensin II antagonist therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with angiotensin II antagonists should be stopped immediately, and, if appropriate, alternative therapy should be started (see sections 4.3 and 4.6).</p><p>Other:</p><p>As with any antihypertensive agent, excessive blood pressure decrease in patients with ischaemic heart disease or ischaemic cerebrovascular disease could result in a myocardial infarction or stroke.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Potential interactions related to the Sevikar combination:</p><p>To be taken into account with concomitant use</p><p>Other antihypertensive agents:</p><p>The blood pressure lowering effect of Sevikar can be increased by concomitant use of other antihypertensive medicinal products (e.g. alpha blockers, diuretics).</p><p>Potential interactions related to the olmesartan medoxomil component of Sevikar: Concomitant use not recommended</p><p>Medicinal products affecting potassium levels:</p><p>Concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium or other medicinal products that may increase serum potassium levels (e.g. heparin, ACE inhibitors) may lead to increases in serum potassium (see section 4.4). If medicinal products which affect potassium levels are to be prescribed in combination with Sevikar, monitoring of serum potassium levels is recommended.</p><p>Lithium:</p><p>Increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with angiotensin converting enzyme inhibitors and, rarely, with angiotensin II antagonists. Therefore concomitant use of Sevikar and lithium is not recommended (see section 4.4). If concomitant use of Sevikar and lithium proves necessary, careful monitoring of serum lithium levels is recommended. Concomitant use requiring caution</p><p>Non-steroidal anti-inflammatory medicinal products (NSAIDs) including selective COX-2 inhibitors, acetylsalicylic acid (&gt; 3 g/day) and non-selective NSAIDs:</p><p>When angiotensin II antagonists are administered simultaneously with NSAIDs, attenuation of the antihypertensive effect may occur. Furthermore, concomitant use of angiotensin II antagonists and NSAIDs may increase the risk of worsening of renal function and may lead to an increase in serum potassium. Therefore monitoring of renal function at the beginning of such concomitant therapy is recommended, as well as adequate hydration of the patient.</p><p>Additional information</p><p>After treatment with antacid (aluminium magnesium hydroxide), a modest reduction in bioavailability of olmesartan was observed.</p><p>Olmesartan medoxomil had no significant effect on the pharmacokinetics or pharmacodynamics of warfarin or the pharmacokinetics of digoxin. Coadministration</p><p>&nbsp;</p><p>of olmesartan medoxomil with pravastatin had no clinically relevant effects on the pharmacokinetics of either component in healthy subjects.</p><p>Olmesartan had no clinically relevant inhibitory effects on human cytochrome P450 enzymes 1A1/2, 2A6, 2C8/9, 2C19, 2D6, 2E1 and 3A4 <em>in vitro</em>, and had no or minimal inducing effects on rat cytochrome P450 activities. No clinically relevant interactions between olmesartan and medicinal products metabolised by the above cytochrome P450 enzymes are expected.</p><p>Potential interactions related to the amlodipine component of Sevikar: Effects of other medicinal products on amlodipine</p><p>CYP3A4 inhibitors:</p><p>Concomitant use of amlodipine with strong or moderate CYP3A4 inhibitors (protease inhibitors, azole antifungals, macrolides like erythromycin or clarithromycin, verapamil or diltiazem) may give rise to significant increase in amlodipine exposure. The clinical translation of these PK variations may be more pronounced in the elderly. Clinical monitoring and dose adjustment may thus be required.</p><p>CYP3A4 inducers:</p><p>There is no data available regarding the effect of CYP3A4 inducers on amlodipine. The concomitant use of CYP3A4 inducers (i.e. rifampicin, hypericum perforatum) may give a lower plasma concentration of amlodipine. Amlodipine should be used with caution together with CYP3A4 inducers.</p><p>Administration of amlodipine with grapefruit or grapefruit juice is not recommended as bioavailability may be increased in some patients resulting in increased blood pressure lowering effects.</p><p><strong>Dantrolene (infusion): </strong>In animals, lethal ventricular fibrillation and cardiovascular collapse are observed in association with hyperkalemia after administration of verapamil and intravenous dantrolene. Due to risk of hyperkalemia, it is recommended that the co-administration of calcium channel blockers such as amlodipine be avoided in patients susceptible to malignant hyperthermia and in the management of malignant hyperthermia.</p><p>Effects of amlodipine on other medicinal products</p><p>The blood pressure lowering effects of amlodipine adds to the blood pressure- lowering effects of other antihypertensive agents.</p><p>In clinical interaction studies, amlodipine did not affect the pharmacokinetics of atorvastatin, digoxin, warfarin or cyclosporin.</p><p>Simvastatin: Co-administration of multiple doses of 10 mg of amlodipine with 80 mg simvastatin resulted in a 77% increase in exposure to simvastatin compared to simvastatin alone. Limit the dose of simvastatin in patients on amlodipine to 20 mg daily.</p><p>Dual RAAS Blockade:</p><p>The combination of Sevikar with Aliskiren, ACEIs or other ARBs is contraindicated in patients with diabetes mellitus or renal impairment.</p><p>Dual blockade (e.g by adding ACE inhibitor to Sevikar ) should not be used, especially in patients with Kidney problems.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy (see section 4.3)</p><p>&nbsp;</p><p>There are no data about the use of Sevikar in pregnant patients. Animal reproductive toxicity studies with Sevikar have not been performed.</p><p>Olmesartan medoxomil (active ingredient of Sevikar)</p><p>Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during the first trimester of pregnancy has not been conclusive; however a small increase in risk cannot be excluded. Whilst there is no controlled epidemiological data on the risk with angiotensin II antagonists, similar risks may exist for this class of drugs. Unless continued angiotensin II antagonists therapy is considered essential, patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with angiotensin II antagonists should be stopped immediately, and, if appropriate, alternative therapy should be started.</p><p>Exposure to angiotensin II antagonists therapy during the second and third trimesters is known to induce human fetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia). (See section 5.3).</p><p>Should exposure to angiotensin II antagonists have occurred from the second trimester on, ultrasound check of renal function and skull is recommended. Infants whose mothers have taken angiotensin II antagonists should be closely observed for hypotension (see sections 4.3 and 4.4).</p><p>Amlodipine (active ingredient of Sevikar)</p><p>Data on a limited number of exposed pregnancies do not indicate that amlodipine or other calcium receptor antagonists have a harmful effect on the health of the fetus. However, there may be a risk of prolonged delivery.</p><p>As a consequence, Sevikar is not recommended during the first trimester of pregnancy and is contraindicated during the second and third trimesters of pregnancy (see sections 4.3 and 4.4).</p><p>Lactation</p><p>Olmesartan is excreted into the milk of lactating rats. However, it is not known whether olmesartan passes into human milk. It is not known whether amlodipine is excreted in breast milk. Similar calcium channel blockers of the dihydropyridine type are excreted in breast milk.</p><p>Because no information is available regarding the use of olmesartan and amlodipine during breast-feeding, Sevikar is not recommended and alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.</p><p>Fertility</p><p>Reversible biochemical changes in the head of spermatozoa have been reportedin some patients treated by calcium channel blockers. Clinical data are insufficient regarding the potential effect of amlodipine on fertility. In one rat study, adverse effects were found on male fertility (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sevikar can have minor or moderate influence on the ability to drive and use machines.</p><p>&nbsp;</p><p>Dizziness, headache, nausea or fatigue may occasionally occur in patients taking antihypertensive therapy, which may impair the ability to react. Caution is recommended especially at the start of treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Summary of the safety profile:</strong></p><p>The most commonly reported adverse reactions during treatment with Sevikar are peripheral oedema (11.3%), headache (5.3%) and dizziness (4.5%).</p><p>Adverse reactions from Sevikar in clinical trials, post-authorisation safety studies and spontaneous reporting are summarised in the below table as well as adverse reactions from the individual components olmesartan medoxomil and amlodipine based on the known safety profile of these substances.</p><p>b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tabulated list of Adverse reaction:</p><p>The following terminologies have been used in order to classify the occurrence of adverse reactions:</p><p>Very common (&ge;1/10) Common (&ge;1/100 to &lt;1/10)</p><p>Uncommon (&ge;1/1,000 to &lt;1/100)</p><p>Rare (&ge;1/10,000 to &lt;1/1,000)</p><p>Very rare (&lt;1/10,000), not known (cannot be estimated from the available data)</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>MedDRA System&nbsp;&nbsp;&nbsp;&nbsp; Organ Class</p></td><td rowspan="2" style="vertical-align:top"><p>Adverse reactions</p></td><td colspan="3" style="vertical-align:top"><p>Frequency</p></td></tr><tr><td style="vertical-align:top"><p>Olmesartan/Amlodipine combination</p></td><td style="vertical-align:top"><p>Olmesartan</p></td><td style="vertical-align:top"><p>Amlodipine</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Blood&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Leukocytopenia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Thrombocytopenia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Allergic reaction /Drug hypersensitivity</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Anaphylactic reaction</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>Hyperglycaemia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Hyperkalaemia</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Hypertriglyceridaemia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Hyperuricaemia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td rowspan="6" style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>Confusion</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Depression</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Insomnia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Irritability</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Libido decreased</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Mood&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changes</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(including anxiety)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td rowspan="13" style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Dysgeusia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common (especially at&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the</p><p>beginning of treatment)</p></td></tr><tr><td style="vertical-align:top"><p>Hypertonia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Hypoaesthesia</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Lethargy</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Paraesthesia</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Peripheral neuropathy</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Postural dizziness</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Sleep disorder</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Somnolence</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Syncope</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Tremor</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>Visual&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; disturbance (including diplopia)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Ear&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and</p><p>labyrinth disorders</p></td><td style="vertical-align:top"><p>Tinnitus</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Vertigo</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>Angina pectoris</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon (incl. aggravation of&nbsp;&nbsp;&nbsp;&nbsp; angina pectoris)</p></td></tr><tr><td style="vertical-align:top"><p>Arrhythmia&nbsp;&nbsp;&nbsp; (including bradycardia, ventricular tachycardia and atrial fibrillation)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Myocardial infarction</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Palpitations</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Tachycardia</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="4" style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Hypotension</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Orthostatic hypotension</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Flushing</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Vasculitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p>Respiratory, thoracic&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and mediastinal disorders</p></td><td style="vertical-align:top"><p>Bronchitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Cough</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Dyspnoea</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Pharyngitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rhinitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td rowspan="13" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Abdominal pain</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Altered bowel habits (including diarrhoea and constipation)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Constipation</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Diarrhoea</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Dry mouth</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Dyspepsia</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Gastritis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Gastroenteritis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Gingival hyperplasia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Pancreatitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Upper abdominal pain</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Hepato-biliary disorders</p></td><td style="vertical-align:top"><p>Hepatic&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; enzymes increased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Very&nbsp;&nbsp;&nbsp;&nbsp; rare (mostly consistent with cholestasis)</p></td></tr><tr><td style="vertical-align:top"><p>Hepatitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Jaundice</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Autoimmune hepatitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Unknown</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Skin&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and</p></td><td style="vertical-align:top"><p>Alopecia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="14" style="vertical-align:top"><p>subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Angioneurotic oedema</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Allergic dermatitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Erythema multiforme</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Exanthema</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Exfoliative dermatitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Hyperhydrosis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Photosensitivity</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Pruritus</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Purpura</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Quincke oedema</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Rash</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Skin discoloration</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Stevens-Johnson syndrome</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Urticaria</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td rowspan="8" style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>Ankle swelling</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Arthralgia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Arthritis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Back pain</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Muscle spasm</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Myalgia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Pain in extremity</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Skeletal pain</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td rowspan="8" style="vertical-align:top"><p>Renal&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and urinary disorders</p></td><td style="vertical-align:top"><p>Acute renal failure</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Haematuria</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Increased&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; urinary frequency</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Micturition disorder</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Nocturia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Pollakiuria</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Renal insufficiency</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Urinary tract infection</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>Reproductive system&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and breast disorders</p></td><td style="vertical-align:top"><p>Erectile dysfunction/impotence</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Gynecomastia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td rowspan="11" style="vertical-align:top"><p>General disorders&nbsp;&nbsp;&nbsp;&nbsp; and administration site conditions</p></td><td style="vertical-align:top"><p>Asthenia</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Chest pain</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Face oedema</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Fatigue</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Influenza-like symptoms</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Lethargy</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Malaise</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Oedema</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Pain</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Peripheral oedema</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Pitting oedema</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td rowspan="8" style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>Blood&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; creatinine increased</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Blood&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; creatine phosphokinase increased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Blood&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; potassium decreased</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Blood urea increased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Blood&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; uric&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; acid increased</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Gamma&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; glutamyl transferase increased</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Weight decrease</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Weight increase</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr></tbody></table><p>&nbsp;</p><p>c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Description of selected adverse reaction:</p><p>Single cases of rhabdomyolysis have been reported in temporal association with the intake of angiotensin II receptor blockers. Single cases of extrapyramidal syndrome have been reported in patients treated with amlodipine.</p><p>&nbsp;</p><p>Cases of autoimmune hepatitis with a latency of few months to years have been reported post- marketing, that were reversible after the withdrawal of olmesartan.</p><p>&nbsp;</p><p>Post Marketing Experience:</p><p>Data from one controlled trial and an epidemiologic study have suggested that high- dose olmesartan may increase cardiovascular (CV) risk in diabetic patients, but the overall data are not conclusive. The randomized, placebo-controlled, double-blind ROADMAP trial (Randomized Olmesartan And Diabetes MicroAlbuminuria Prevention trial, n=4447) examined the use of olmesartan, 40 mg daily, vs. placebo in patients with type 2 diabetes mellitus, normoalbuminuria, and at least one additional risk factor for CV disease. The trial met its primary endpoint, decrease in time-to-onset of microalbuminuria, but olmesartan had no beneficial effect on decline in glomerular filtration rate (GFR). There was a finding of increased CV mortality (adjudicated sudden cardiac death, fatal myocardial infarction, fatal stroke, revascularization death) in the olmesartan group compared to the placebo group (15 olmesartan vs. 3 placebo, HR 4.9, 95% confidence interval [CI], 1.4, 17), but the risk of non-fatal myocardial infarction was lower with olmesartan (HR 0.64, 95% CI 0.35, 1.18).</p><p>The epidemiologic study included patients 65 years and older with overall exposure of &gt;300,000 patient-years. In the sub-group of diabetic patients receiving high-dose olmesartan (40 mg/d) for &gt; 6 months, there appeared to be an increased risk of death (HR 2.0, 95% CI 1.1, 3.8) compared to similar patients taking other angiotensin receptor blockers. In contrast, high-dose olmesartan use innon-diabetic patients appeared to be associated with a decreased risk of death (HR 0.46, 95% CI 0.24, 0.86) compared to similar patients taking other angiotensin receptor blockers. No differences were observed between the groups receiving lower doses of olmesartan compared to other angiotensin blockers or those receiving therapy for &lt; 6 months.</p><p>Overall, these data raise a concern of a possible increased CV risk associated with the use of high-dose olmesartan in diabetic patients. There are, however, concerns with the credibility of the finding of increased CV risk, notably the observation in the large epidemiologic study for a survival benefit in non-diabetics of a magnitude similar to the adverse finding in diabetics.</p><p>d.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other special population:</p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Renal impairment and kidney transplantation:</p><p>When Sevikar is used in patients with impaired renal function, periodic monitoring of serum potassium and creatinine levels is recommended. Use of Sevikar is not recommended in patients with severe renal impairment (creatinine clearance &lt; 20 mL/min) (see sections 4.2, 5.2). There is no experience of the administration of Sevikar in patients with a recent kidney transplant or in patients with end-stage renal impairment (i.e. creatinine clearance &lt; 12 mL/min).</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hepatic impairment:</p><p>Exposure to amlodipine and olmesartan medoxomil is increased in patients with hepatic impairment (see section 5.2). Care should be taken when Sevikar is administered in patients with mild to moderate hepatic impairment. In moderately impaired patients, the dose of olmesartan medoxomil should not exceed 20 mg (see section 4.2). In patients with impaired hepatic function, amlodipine should be initiated at the lower end of the dosing range and caution should be used, both on initial treatment and when increasing the</p><p>&nbsp;</p><p>dose. Use of Sevikar in patients with severe hepatic impairment is contraindicated (see section 4.3).</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Elderly patients:</p><p>In the elderly, increase of the dosage should take place with care (see section 5.2).</p><p>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pregnancy:</p><p>Angiotensin II antagonists should not be initiated during pregnancy. Unless continued angiotensin II antagonist therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with angiotensin II antagonists should be stopped immediately, and, if appropriate, alternative therapy should be started (see sections 4.3 and 4.6).</p><p>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other:</p><p>As with any antihypertensive agent, excessive blood pressure decrease in patients with ischaemic heart disease or ischaemic cerebrovascular disease could result in a myocardial infarction or stroke.</p><p>-To report any side effect (s)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia :</strong></p><p><strong>&nbsp;</strong></p><p><!--[if gte vml 1]><o:wrapblock><v:shapetype
  id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="_x0000_s1027" type="#_x0000_t202" style='position:absolute;
  margin-left:84.35pt;margin-top:12pt;width:504.6pt;height:70.75pt;z-index:-15728128;
  mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' filled="f" strokeweight=".48pt">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoBodyText align=left style='margin-top:1.0pt;margin-right:0in;
     margin-bottom:0in;margin-left:11.85pt;margin-bottom:.0001pt;text-align:
     left;text-indent:-6.5pt;mso-list:l3 level1 lfo3;tab-stops:11.9pt'><![if !supportLists]><span
     style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;
     </span></span><![endif]><span dir=LTR></span><span style='color:black;
     mso-color-alt:windowtext;background:yellow'>The<span style='letter-spacing:
     -.2pt'> </span>National<span style='letter-spacing:-.15pt'> </span>Pharmacovigilance<span
     style='letter-spacing:-.15pt'> </span>Center<span style='letter-spacing:
     -.15pt'> </span>(NPC) <span style='letter-spacing:-.05pt'><span
     style='mso-spacerun:yes'> </span></span></span><o:p></o:p></p>
     <p class=MsoBodyText align=left style='margin-top:.95pt;margin-right:0in;
     margin-bottom:0in;margin-left:14.65pt;margin-bottom:.0001pt;text-align:
     left;text-indent:-9.25pt;mso-list:l3 level1 lfo3;tab-stops:14.65pt'><![if !supportLists]><span
     style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
     </span></span><![endif]><span dir=LTR></span><span style='color:black;
     mso-color-alt:windowtext;background:yellow'>SFDA<span style='letter-spacing:
     -.1pt'> </span>Call<span style='letter-spacing:-.2pt'> </span>Center:<span
     style='letter-spacing:-.1pt'> </span>19999</span><o:p></o:p></p>
     <p class=MsoBodyText align=left style='margin-top:1.05pt;margin-right:
     0in;margin-bottom:0in;margin-left:11.85pt;margin-bottom:.0001pt;
     text-align:left;text-indent:-6.5pt;mso-list:l3 level1 lfo3;tab-stops:11.9pt'><![if !supportLists]><span
     style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;
     </span></span><![endif]><span dir=LTR></span><a
     href="mailto:npc.drug@sfda.gov.sa"><span style='color:black;mso-color-alt:
     windowtext;background:yellow;text-decoration:none;text-underline:none'>E-mail:<span
     style='letter-spacing:-.3pt'> </span>npc.drug@sfda.gov.sa</span></a><o:p></o:p></p>
     <p class=MsoBodyText align=left style='margin-top:.95pt;margin-right:0in;
     margin-bottom:0in;margin-left:11.85pt;margin-bottom:.0001pt;text-align:
     left;text-indent:-6.5pt;mso-list:l3 level1 lfo3;tab-stops:11.9pt'><![if !supportLists]><span
     style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;
     </span></span><![endif]><span dir=LTR></span><span style='color:black;
     mso-color-alt:windowtext;background:yellow'>Website:<span
     style='letter-spacing:-.4pt'> </span>https://ade.sfda.gov.sa</span><o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="679" height="100" alt="Text Box: -	The National Pharmacovigilance Center (NPC)  
-	SFDA Call Center: 19999
-	E-mail: npc.drug@sfda.gov.sa
-	Website: https://ade.sfda.gov.sa
" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other GCC states /other countries</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:10.0pt;mso-bidi-font-size:12.0pt'><span style='mso-element:
field-begin;mso-field-lock:yes'></span><span style='mso-spacerun:yes'> </span>SHAPE
<span style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:
field-separator'></span></span><![endif]--><!--[if gte vml 1]><v:shape id="_x0000_s1026"
 type="#_x0000_t202" style='width:390.6pt;height:17.3pt;mso-left-percent:-10001;
 mso-top-percent:-10001;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:char;mso-position-vertical:absolute;
 mso-position-vertical-relative:line;mso-left-percent:-10001;mso-top-percent:-10001'
 filled="f" strokeweight=".48pt">
 <v:textbox inset="0,0,0,0">
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoBodyText align=left style='margin-top:1.1pt;margin-right:0in;
    margin-bottom:0in;margin-left:5.35pt;margin-bottom:.0001pt;text-align:left'>-Please<span
    style='letter-spacing:-.3pt'> </span>contact<span style='letter-spacing:
    -.2pt'> </span>the<span style='letter-spacing:-.2pt'> </span>relevant<span
    style='letter-spacing:-.1pt'> </span>competent<span style='letter-spacing:
    -.1pt'> </span>authority.<o:p></o:p></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:shape><![endif]--><img width="526" height="29" alt="Text Box: -Please contact the relevant competent authority." src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:10.0pt;mso-bidi-font-size:12.0pt'><v:shape id="_x0000_i1025"
 type="#_x0000_t75" style='width:390.6pt;height:17.3pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Symptoms:</p><p>There is no experience of overdose with Sevikar. The most likely effects of olmesartan medoxomil over dosage are hypotension and tachycardia; bradycardia could be encountered if parasympathetic (vagal) stimulation occurred. Amlodipine over dosage can be expected to lead to excessive peripheral vasodilatation with marked hypotension and possibly a reflex tachycardia. Marked and potentially prolonged systemic hypotension up to and including shock with fatal outcome has been reported.</p><p>Non-cardiogenic pulmonary oedema has rarely been reported as a consequence of amlodipine overdose that may manifest with a delayed onset (24-48 hours post- ingestion) and require ventilatory support. Early resuscitative measures (including fluid overload) to maintain perfusion and cardiac output may be precipitating factors.</p><p>&nbsp;</p><p>Treatment:</p><p>If intake is recent, gastric lavage may be considered. In healthy subjects, the administration of activated charcoal immediately or up to 2 hours after ingestion of amlodipine has been shown to reduce substantially the absorption of amlodipine.</p><p>Clinically significant hypotension due to an overdose of Sevikar requires active support of the cardiovascular system, including close monitoring of heart and lung function, elevation of the extremities, and attention to circulating fluid volume and urine output. A vasoconstrictor may be helpful in restoring vascular tone and blood pressure, provided that there is no contraindication to its use. Intravenous calcium gluconate may be beneficial in reversing the effects of calcium channel blockade.</p><p>Since amlodipine is highly protein-bound, dialysis is not likely to be of benefit. The dialysability of olmesartan is unknown.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>5.1&nbsp;&nbsp; </em></strong>Pharmacotherapeutic&nbsp;&nbsp; group:&nbsp;&nbsp; Angiotensin&nbsp;&nbsp; II&nbsp;&nbsp; antagonists&nbsp;&nbsp; and&nbsp;&nbsp; calcium&nbsp;&nbsp;&nbsp;&nbsp; channel blockers, ATC code C09DB02<em>.</em></p><p>Mechanism of action</p><p>Sevikar is a combination of an angiotensin II receptor antagonist, olmesartan medoxomil, and a calcium channel blocker, amlodipine besilate. The combination of these active ingredients has an additive antihypertensive effect, reducing blood pressure to a greater degree than either component alone.</p><p>Clinical efficacy and safety Sevikar</p><p>In an 8-week, double-blind, randomised, placebo-controlled factorial design study in 1940 patients (71% Caucasian and 29% non-Caucasian patients), treatment with each combination dose of Sevikar resulted in significantly greater reductions in diastolic and systolic blood pressures than the respective monotherapy components. The mean change in systolic/diastolic blood pressure was dose-dependent: -24/-14 mmHg (20 mg/5 mg combination), -25/-16 mmHg (40 mg/5 mg combination) and - 30/-19 mmHg (40 mg/10 mg combination).</p><p>Sevikar 40 mg/5 mg reduced seated systolic/diastolic blood pressure by an additional 2.5/1.7 mmHg over Sevikar 20 mg/5 mg. Similarly Sevikar 40 mg/10 mg reduced seated systolic/diastolic blood pressure by an additional 4.7/3.5 mmHg over Sevikar 40 mg/5 mg.</p><p>The proportions of patients reaching blood pressure goal (&lt; 140/90 mmHg for non- diabetic patients and &lt; 130/80 mmHg for diabetic patients) were 42.5%, 51.0% and 49.1% for Sevikar 20 mg/5 mg, 40 mg/5 mg and 40 mg/10 mg respectively.</p><p>The majority of the antihypertensive effect of Sevikar was generally achieved within the first 2 weeks of therapy.</p><p>A second double-blind, randomised, placebo-controlled study evaluated the effectiveness of adding amlodipine to the treatment in Caucasian patients whose blood pressure was inadequately controlled by 8 weeks of monotherapy with 20 mg olmesartan medoxomil.</p><p>In patients who continued to receive only 20 mg olmesartan medoxomil, systolic/diastolic blood pressure was reduced by -10.6/ -7.8 mmHg after a further 8 weeks. The addition of 5 mg amlodipine for 8 weeks resulted in a reduction in systolic/diastolic blood pressure of -16.2/-10.6 mmHg (p = 0.0006).</p><p>The proportion of patients reaching blood pressure goal (&lt; 140/90 mmHg for non- diabetic patients and &lt; 130/80 mmHg for diabetic patients) was 44.5% for the 20 mg/5 mg combination compared to 28.5% for 20 mg olmesartan medoxomil.</p><p>A further study evaluated the addition of various doses of olmesartan medoxomil in Caucasian patients whose blood pressure was not adequately controlled by 8 weeks of monotherapy with 5 mg amlodipine.</p><p>&nbsp;</p><p>In patients who continued to receive only 5 mg amlodipine, systolic/diastolic blood pressure was reduced by -9.9/ -5.7 mmHg after a further 8 weeks. The addition of 20 mg olmesartan medoxomil resulted in a reduction in systolic/diastolic blood pressure of -15.3/-9.3 mmHg and the addition of 40 mg olmesartan medoxomil resulted in a reduction in systolic/diastolic blood pressure of -16.7/-9.5 mmHg (p &lt; 0.0001).</p><p>The proportions of patients reaching blood pressure goal (&lt; 140/90 mmHg for non- diabetic patients and &lt; 130/80 mmHg for diabetic patients) was 29.9% for the group who continued to receive 5 mg amlodipine alone, 53.5% for Sevikar 20 mg/5 mg and 50.5% for Sevikar 40 mg/5 mg.</p><p>Randomised data in uncontrolled hypertensive patients, comparing the use of medium dose Sevikar combination therapy versus escalation to top dose monotherapy of amlodipine or olmesartan, are not available.</p><p>The three studies performed confirmed that the blood pressure lowering effect of Sevikar once daily was maintained throughout the 24-hour dose interval, with trough- to-peak ratios of 71% to 82% for systolic and diastolic response and with 24- hour effectiveness being confirmed by ambulatory blood pressure monitoring.</p><p>The antihypertensive effect of Sevikar was similar irrespective of age and gender, and was similar in patients with and without diabetes.</p><p>In two open-label, non-randomised extension studies, sustained efficacy using Sevikar 40 mg/5 mg was demonstrated at one year for 49 - 67% of patients.</p><p>Olmesartan medoxomil (active ingredient of Sevikar)</p><p>The olmesartan medoxomil component of Sevikar is a selective angiotensin II type 1 (AT1) receptor antagonist. Olmesartan medoxomil is rapidly converted to the pharmacologically active metabolite, olmesartan. Angiotensin II is the primary vasoactive hormone of the renin-angiotensin-aldosterone system and plays a significant role in the pathophysiology of hypertension. The effects of angiotensin II include vasoconstriction, stimulation of the synthesis and release of aldosterone, cardiac stimulation and renal reabsorption of sodium. Olmesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by blocking its binding to the AT1 receptor in tissues including vascular smooth muscle and the adrenal gland. The action of olmesartan is independent of the source or route of synthesis of angiotensin II. The selective antagonism of the angiotensin II (AT1) receptors by olmesartan results in increases in plasma renin levels and angiotensin I and II concentrations, and some decrease in plasma aldosterone concentrations.</p><p>In hypertension, olmesartan medoxomil causes a dose-dependent, long-lasting reduction in arterial blood pressure. There has been no evidence of first-dose hypotension, of tachyphylaxis during long-term treatment, or of rebound hypertension after abrupt cessation of therapy.</p><p>Following once daily administration to patients with hypertension, olmesartan medoxomil produces an effective and smooth reduction in blood pressure over the 24 hour dose interval. Once daily dosing produced similar decreases in blood pressure as twice daily dosing at the same total daily dose.</p><p>With continuous treatment, maximum reductions in blood pressure are achieved by 8 weeks after the initiation of therapy, although a substantial proportion of the blood pressure lowering effect is already observed after 2 weeks of treatment.</p><p>The effect of olmesartan medoxomil on mortality and morbidity is not yet known. Amlodipine (active ingredient of Sevikar)</p><p>&nbsp;</p><p>The amlodipine component of Sevikar is a calcium channel blocker that inhibits the transmembrane influx of calcium ions through the potential-dependent L-type channels into the heart and smooth muscle. Experimental data indicate that amlodipine binds to both dihydropyridine and non-dihydropyridine binding sites. Amlodipine is relatively vessel-selective, with a greater effect on vascular smooth muscle cells than on cardiac muscle cells. The antihypertensive effect of amlodipine derives from a direct relaxant effect on arterial smooth muscle, which leads to a lowering of peripheral resistance and hence of blood pressure.</p><p>In hypertensive patients, amlodipine causes a dose-dependent, long-lasting reduction in arterial blood pressure. There has been no evidence of first-dose hypotension, of tachyphylaxis during long-term treatment, or of rebound hypertension after abrupt cessation of therapy.</p><p>Following administration of therapeutic doses to patients with hypertension, amlodipine produces an effective reduction in blood pressure in the supine, sitting and standing positions. Chronic use of amlodipine is not associated with significant changes in heart rate or plasma catecholamine levels. In hypertensive patients with normal renal function, therapeutic doses of amlodipine reduce renal vascular resistance and increase glomerular filtration rate and effective renal plasma flow, without changing filtration fraction or proteinuria.</p><p>In haemodynamic studies in patients with heart failure and in clinical studies based on exercise tests in patients with NYHA class II-IV heart failure, amlodipine was found not to cause any clinical deterioration, as measured by exercise tolerance, left ventricular ejection fraction and clinical signs and symptoms.</p><p>A placebo-controlled study (PRAISE) designed to evaluate patients with NYHA class III-IV heart failure receiving digoxin, diuretics and ACE inhibitors has shown that amlodipine did not lead to an increase in risk of mortality or combined mortality and morbidity in patients with heart failure.</p><p>In a follow-up, long-term, placebo controlled study (PRAISE-2) of amlodipine in patients with NYHA III and IV heart failure without clinical symptoms or objective findings suggestive of underlying ischaemic disease, on stable doses of ACE inhibitors, digitalis, and diuretics, amlodipine had no effect on total or cardiovascular mortality. In this same population amlodipine was associated with increased reports of pulmonary oedema despite no significant difference in the incidence of worsening heart failure as compared to placebo.</p><p>Treatment to prevent heart attack trial (ALLHAT)</p><p>A randomized double-blind morbidity-mortality study called the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) was performed to compare newer drug therapies: amlodipine 2.5-10 mg/d (calcium channel blocker) or lisinopril 10-40 mg/d (ACE-inhibitor) as first-line therapies to that of the thiazide- diuretic, chlorthalidone 12.5-25 mg/d in mild to moderate hypertension.&rdquo;</p><p>A total of 33,357 hypertensive patients aged 55 or older were randomized and followed for a mean of 4.9 years. The patients had at least one additional CHD risk factor, including: previous myocardial infarction or stroke (&gt; 6 months prior to enrollment) or documentation of other atherosclerotic CVD (overall 51.5%), type 2 diabetes (36.1%), HDL-C &lt; 35 mg/dL (11.6%), left ventricular hypertrophy diagnosed by electrocardiogram or echocardiography (20.9%), current cigarette smoking (21.9%).</p><p>&nbsp;</p><p>The primary endpoint was a composite of fatal CHD or non-fatal myocardial infarction. There was no significant difference in the primary endpoint between amlodipine-based therapy and chlorthalidone-based therapy: RR 0.98 95% CI (0.90- 1.07) p=0.65. Among secondary endpoints, the incidence of heart failure (component of a composite combined cardiovascular endpoint) was significantly higher in the amlodipine group as compared to the chlorthalidone group (10.2% vs. 7.7%, RR 1.38, 95% CI [1.25-1.52] p&lt;0.001). However, there was no significant difference in all-cause mortality between amlodipine-based therapy and chlorthalidone-based therapy (RR 0.96 95% CI [0.89-1.02] p=0.20).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>5.1&nbsp;&nbsp; </strong>Following oral intake of Sevikar, peak plasma concentrations of olmesartan and amlodipine are reached at 1.5 &ndash; 2 h and 6 &ndash; 8 hours, respectively. The rate and extent of absorption of the two active substances from Sevikar are equivalent to the rate and extent of absorption following intake of the two components as separate tablets. Food does not affect the bioavailability of olmesartan and amlodipine from Sevikar.</p><p>Olmesartan medoxomil (active ingredient of Sevikar) Absorption and distribution:</p><p>Olmesartan medoxomil is a prodrug. It is rapidly converted to the pharmacologically active metabolite, olmesartan, by esterases in the gut mucosa and in portal blood during absorption from the gastrointestinal tract. No intact olmesartan medoxomil or intact side chain medoxomil moiety have been detected in plasma or excreta. The mean absolute bioavailability of olmesartan from a tablet formulation was 25.6%.</p><p>The mean peak plasma concentration (Cmax) of olmesartan is reached within about</p><p>2 hours after oral dosing with olmesartan medoxomil, and olmesartan plasma concentrations increase approximately linearly with increasing single oral doses up to about 80 mg.</p><p>Food had minimal effect on the bioavailability of olmesartan and therefore olmesartan medoxomil may be administered with or without food.</p><p>No clinically relevant gender-related differences in the pharmacokinetics of olmesartan have been observed.</p><p>Olmesartan is highly bound to plasma protein (99.7%), but the potential for clinically significant protein binding displacement interactions between olmesartan and other highly bound coadministered active substances is low (as confirmed by the lack of a clinically significant interaction between olmesartan medoxomil and warfarin). The binding of olmesartan to blood cells is negligible. The mean volume of distribution after intravenous dosing is low (16 &ndash; 29 L).</p><p>Metabolism and elimination:</p><p>Total plasma clearance of olmesartan was typically 1.3 L/h (CV, 19%) and was relatively slow compared to hepatic blood flow (ca 90 L/h). Following a single oral dose of 14C-labelled olmesartan medoxomil, 10% &ndash; 16% of the administered radioactivity was excreted in the urine (the vast majority within 24 hours of dose administration) and the remainder of the recovered radioactivity was excreted in the faeces. Based on the systemic availability of 25.6%, it can be calculated that absorbed olmesartan is cleared by both renal excretion (ca 40%) and hepato-biliary excretion (ca 60%). All recovered radioactivity was identified as olmesartan. No other significant metabolite was detected. Enterohepatic recycling of olmesartan is</p><p>&nbsp;</p><p>minimal. Since a large proportion of olmesartan is excreted via the biliary route, use in patients with biliary obstruction is contraindicated (see section 4.3).</p><p>The terminal elimination half life of olmesartan is between 10 and 15 hours after multiple oral dosing. Steady state is reached after the first few doses and no further accumulation is evident after 14 days of repeated dosing. Renal clearance is approximately 0.5 &ndash; 0.7 L/h and is independent of dose.</p><p>Amlodipine (active ingredient of Sevikar) Absorption and distribution:</p><p>After oral administration of therapeutic doses, amlodipine is well absorbed with peak blood levels between 6-12 hours post dose. Absolute bioavailability has been estimated to be between 64 and 80%. The volume of distribution is approximately</p><p>21 l/kg. In vitro studies have shown that approximately 97.5% of circulating amlodipine is bound to plasma proteins.</p><p>The absorption of amlodipine is unaffected by the concomitant intake of food. Metabolism and elimination:</p><p>The terminal plasma elimination half life is about 35-50 hours and is consistent with once daily dosing. Amlodipine is extensively metabolised by the liver to inactive metabolites with 10% of the parent compound and 60% of metabolites excreted in the urine.</p><p>Olmesartan medoxomil and amlodipine (active ingredients of Sevikar)</p><p>Special populations</p><p>Paediatric population (age below 18 years):</p><p>No pharmacokinetic data in paediatric patients are available. Elderly (age 65 years or over):</p><p>In hypertensive patients, the olmesartan AUC at steady state is increased by ca 35% in elderly patients (65 &ndash; 75 years old) and by ca 44% in very elderly patients (&ge; 75 years old) compared with the younger age group (see section 4.2). This may be at least in part related to a mean decrease in renal function in this group of patients. The recommended dosage regimen for elderly patients is, however, the same, although caution should be exercised when increasing the dosage.</p><p>The time to reach peak plasma concentrations of amlodipine is similar in elderly and younger subjects. Amlodipine clearance tends to be decreased with resulting increases in AUC and elimination half life in elderly patients. Increases in AUC and elimination half life in patients with congestive heart failure were as expected for the patient age group in this study (see Section 4.4).</p><p>Renal impairment:</p><p>In renally impaired patients, the olmesartan AUC at steady state increased by 62%, 82% and 179% in patients with mild, moderate and severe renal impairment, respectively, compared to healthy controls (see sections 4.2, 4.4).</p><p>Amlodipine is extensively metabolised to inactive metabolites. Ten percent of the substance is excreted unchanged in the urine. Changes in amlodipine plasma concentration are not correlated with the degree of renal impairment. In these patients, amlodipine may be administered at the normal dosage. Amlodipine is not dialysable.</p><p>Hepatic impairment:</p><p>After single oral administration, olmesartan AUC values are 6% and 65% higher in mildly and moderately hepatically impaired patients, respectively, than in their</p><p>&nbsp;</p><p>corresponding matched healthy controls. The unbound fraction of olmesartan at 2 hours post-dose in healthy subjects, in patients with mild hepatic impairment and in patients with moderate hepatic impairment is 0.26%, 0.34% and 0.41%, respectively. Following repeated dosing in patients with moderate hepatic impairment, olmesartan mean AUC is again about 65% higher than in matched healthy controls. Olmesartan mean Cmax values are similar in hepatically-impaired and healthy subjects. Olmesartan medoxomil has not been evaluated in patients with severe hepatic impairment (see sections 4.2, 4.4).</p><p>Very limited clinical data are available regarding amlodipine administration in patients with hepatic impairment. The clearance of amlodipine is decreased and the half-life is prolonged in patients with impaired hepatic function, resulting in an increase in AUC of about 40% &ndash; 60% (see sections 4.2, 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>5.1&nbsp;&nbsp; </strong>Based on the non-clinical toxicity profile of each substance, no exacerbation of toxicities for the combination is expected, because each substance has different targets, i.e. the kidneys for olmesartan medoxomil and the heart for amlodipine.</p><p>In a 3-month, repeat-dose toxicity study of orally administered olmesartan medoxomil/amlodipine in combination in rats the following alterations were observed: decreases in red blood cell count-related parameters and kidney changes both of which might be induced by the olmesartan medoxomil component; alterations in the intestines (luminal dilatation and diffuse mucosal thickening of the ileum and colon), the adrenals (hypertrophy of the glomerular cortical cells and vacuolation of the fascicular cortical cells), and hypertrophy of the ducts in the mammary glands which might be induced by the amlodipine component. These alterations neither augmented any of the previously reported and existing toxicity of the individual agents nor induced any new toxicity, and no toxicologically synergistic effects were observed.</p><p>Olmesartan medoxomil (active ingredient of Sevikar)</p><p>In chronic toxicity studies in rats and dogs, olmesartan medoxomil showed similar effects to other AT1 receptor antagonists and ACE inhibitors: raised blood urea (BUN) and creatinine; reduction in heart weight; reduction of red cell parameters (erythrocytes, haemoglobin, heamatocrit); histological indications of renal damage (regenerative lesions of the renal epithelium, thickening of the basal membrane, dilatation of the tubules). These adverse effects caused by the pharmacological action of olmesartan medoxomil have also occurred in preclinical trials on other AT1 receptor antagonists and ACE inhibitors and can be reduced by simultaneous oral administration of sodium chloride. In both species, increased plasma renin activity and hypertrophy/hyperplasia of the juxtaglomerular cells of the kidney were observed. These changes, which are a typical effect of the class of ACE inhibitors and other AT1 receptor antagonists, would appear to have no clinical relevance.</p><p>Like other AT1 receptor antagonists olmesartan medoxomil was found to increase the incidence of chromosome breaks in cell cultures in vitro. No relevant effects were observed in several in vivo studies using olmesartan medoxomil at very high oral doses of up to 2000 mg/kg. The overall data of a comprehensive genotoxicity testing program suggest that olmesartan is very unlikely to exert genotoxic effects under conditions of clinical use.</p><p>&nbsp;</p><p>Olmesartan medoxomil was not carcinogenic, in a 2-year study in rats nor in two 6- month carcinogenicity studies in transgenic mice.</p><p>In reproductive studies in rats, olmesartan medoxomil did not affect fertility and there was no evidence of a teratogenic effect. In common with other angiotensin II antagonists, survival of offspring was reduced following exposure to olmesartan medoxomil and pelvic dilatation of the kidney was seen after exposure of the dams in late pregnancy and lactation. In common with other antihypertensive agents, olmesartan medoxomil was shown to be more toxic to pregnant rabbits than to pregnant rats, however, there was no indication of a fetotoxic effect.</p><p>Amlodipine (active ingredient of Sevikar) Reproductive toxicology</p><p>Reproductive studies in rats and mice have shown delayed date of delivery, prolonged duration of labour and decreased pup survival at dosages approximately 50 times greater than the maximum recommended dosage for humans based on mg/kg.</p><p>Impairment of fertility</p><p>There was no effect on the fertility of rats treated with amlodipine (males for 64 days and females 14 days prior to mating) at doses up to 10 mg/kg/day (8 times* the maximum recommended human dose of 10 mg on a mg/m2 basis). In another rat study in which male rats were treated with amlodipine besilate for 30 days at a dose comparable with the human dose based on mg/kg, decreased plasma follicle- stimulating hormone and testosterone were found as well as decreases in sperm density and in the number of mature spermatids and Sertoli cells.</p><p>Carcinogenesis, mutagenesis</p><p>Rats and mice treated with amlodipine in the diet for two years, at concentrations calculated to provide daily dosage levels of 0.5, 1.25, and 2.5 mg/kg/day showed no evidence of carcinogenicity. The highest dose (for mice, similar to, and for rats twice* the maximum recommended clinical dose of 10 mg on a mg/m2 basis) was close to the maximum tolerated dose for mice but not for rats.</p><p>Mutagenicity studies revealed no drug related effects at either the gene or chromosome levels.</p><p>*Based on patient weight of 50 kg</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tablet core:</p><p>Sodium Croscarmellose</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Silicified microcrystalline cellulose</p></td></tr><tr><td style="vertical-align:top"><p>Starch, Pregelatinized</p></td></tr><tr><td style="vertical-align:top"><p>Magnesium Stearate</p></td></tr></tbody></table><p>Tablet coat:</p><p>Opadry White</p><p>Opadry Orange</p><p>Opadry Yellow Opadry Red</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                4 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30 &deg;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Forming Aluminium / Aluminium blister pack. Packs of 28 film-coated tablets</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                SAJA Pharmaceuticals
Saudi Arabian Japanese pharmaceutical company limited Jeddah – Saudi Arabia
Under license from Daiichi Sankyo Co. Ltd. Tokyo-Japan
For more information, please contact
Saudi Arabian Japanese pharmaceutical company limited Jeddah – Saudi Arabia
P.O. Box: 42600, Jeddah 21551, KSA Tel: + 966 12 6066667 www.sajapharma.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                August.2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>